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Abstract
BREATHER (PENTA 16) short-cycle therapy (SCT)
(5 days on/2 days off) in young people with chronic human
immunodeficiency virus infection: an open, randomised,
parallel-group Phase II/III trial
Karina Butler,1 Jamie Inshaw,2 Deborah Ford,2 Sarah Bernays,3
Karen Scott,2* Julia Kenny,2,4 Nigel Klein,4 Anna Turkova,2
Lynda Harper,2 Eleni Nastouli,5 Sara Paparini,3 Rahela Choudhury,2
Tim Rhodes,3 Abdel Babiker2 and Diana Gibb2 on behalf of the
PENTA team
1Department of Paediatric Infectious Diseases and Immunology, Our Lady’s Hospital,
Dublin, Ireland
2Medical Research Council Clinical Trials Unit at University College London (MRC CTU at UCL),
London, UK
3Department of Social and Environmental Health Research, Faculty of Public Health Policy,
London School of Hygiene & Tropical Medicine, London, UK
4Infection, Immunity and Inflammation Programme, Institute of Child Health, London, UK
5Virology, University College London Hospital NHS Foundation Trust, London, UK
*Corresponding author karen.scott@ucl.ac.uk
Background: For human immunodeficiency virus (HIV)-infected adolescents facing lifelong antiretroviral
therapy (ART), short-cycle therapy (SCT) with long-acting agents offers the potential for drug-free
weekends, less toxicity, better adherence and cost savings.
Objectives: To determine whether or not efavirenz (EFV)-based ART in short cycles of 5 days on and
2 days off is as efficacious (in maintaining virological suppression) as continuous EFV-based ART
(continuous therapy; CT). Secondary objectives included the occurrence of new clinical HIV events or
death, changes in immunological status, emergence of HIV drug resistance, drug toxicity and changes
in therapy.
Design: Open, randomised, non-inferiority trial.
Setting: Europe, Thailand, Uganda, Argentina and the USA.
Participants: Young people (aged 8–24 years) on EFV plus two nucleoside reverse transcriptase inhibitors
and with a HIV-1 ribonucleic acid level [viral load (VL)] of < 50 copies/ml for > 12 months.
Interventions: Young people were randomised to continue daily ART (CT) or change to SCT (5 days on,
2 days off ART).
Main outcome measures: Follow-up was for a minimum of 48 weeks (0, 4 and 12 weeks and then
12-weekly visits). The primary outcome was the difference between arms in the proportion with
VL> 50 copies/ml (confirmed) by 48 weeks, estimated using the Kaplan–Meier method (12% non-inferiority
margin) adjusted for region and age.
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Results: In total, 199 young people (11 countries) were randomised (n= 99 SCT group, n= 100 CT group)
and followed for a median of 86 weeks. Overall, 53% were male; the median age was 14 years (21%
≥ 18 years); 13% were from the UK, 56% were black, 19% were Asian and 21% were Caucasian; and
the median CD4% and CD4 count were 34% and 735 cells/mm3, respectively. By week 48, only one
participant (CT) was lost to follow-up. The SCT arm had a 27% decreased drug exposure as measured by
the adherence questionnaire and a MEMSCap™ Medication Event Monitoring System (MEMSCap Inc.,
Durham, NC, USA) substudy (median cap openings per week: SCT group, n= 5; CT group, n= 7). By
48 weeks, six participants in the SCT group and seven in the CT group had a confirmed VL > 50 copies/ml
[difference –1.2%, 90% confidence interval (CI) –7.3% to 4.9%] and two in the SCT group and four
in the CT group had a confirmed VL > 400 copies/ml (difference –2.1%, 90% CI –6.2% to 1.9%).
All six participants in the SCT group with a VL > 50 copies/ml resumed daily ART, of whom five were
resuppressed, three were on the same regimen and two with a switch; two others on SCT resumed daily
ART for other reasons. Overall, three participants in the SCT group and nine in the CT group (p= 0.1)
changed ART regimen, five because of toxicity, four for simplification reasons, two because of compliance
issues and one because of VL failure. Seven young people (SCT group, n= 2; CT group, n= 5) had major
non-nucleoside reverse transcriptase inhibitor mutations at VL failure, of whom two (n= 1 SCT group,
n= 1 CT group) had the M184V mutation. Two young people had new Centers for Disease Control B
events (SCT group, n= 1; CT group, n= 1). There were no significant differences between SCT and CT in
grade 3/4 adverse events (13 vs. 14) or in serious adverse events (7 vs. 6); there were fewer ART-related
adverse events in the SCT arm (2 vs. 14; p= 0.02). At week 48 there was no evidence that SCT led to
increased inflammation using an extensive panel of markers. Young people expressed a strong preference
for SCT in a qualitative substudy and in pre- and post-trial questionnaires. In total, 98% of the young
people are taking part in a 2-year follow-up extension of the trial.
Conclusions: Non-inferiority of VL suppression in young people on EFV-based first-line ART with a VL
of < 50 copies/ml was demonstrated for SCT compared with CT, with similar resistance, safety and
inflammatory marker profiles. The SCT group had fewer ART-related adverse events. Further evaluation of
the immunological and virological impact of SCT is ongoing. A limitation of the trial is that the results
cannot be generalised to settings where VL monitoring is either not available or infrequent, nor to use of
low-dose EFV. Two-year extended follow-up of the trial is ongoing to confirm the durability of the SCT
strategy. Further trials of SCT in settings with infrequent VL monitoring and with other antiretroviral drugs
such as tenofovir alafenamide, which has a long intracellular half-life, and/or dolutegravir, which has a
higher barrier to resistance, are planned.
Trial registration: Current Controlled Trials ISRCTN97755073; EUDRACT 2009-012947-40; and
CTA 27505/0005/001–0001.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme (projects 08/53/25 and 11/136/108), the European Commission through EuroCoord
(FP7/2007/2015), the Economic and Social Research Council, the PENTA Foundation, the Medical Research
Council and INSERM SC10-US19, France, and will be published in full in Health Technology Assessment;
Vol. 20, No. 49. See the NIHR Journals Library website for further project information.
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Glossary
Confirmed viral load Viral load tested in a separate blood sample (within a week).
Reproducible viral load Viral load retested in the same blood sample.
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Plain English summary
Human immunodeficiency virus (HIV) is controlled when there is a sufficient level of effective HIV drugsin a person’s bloodstream. For most drugs this means taking them every day, which is challenging for
people living with HIV. Efavirenz stays in the bloodstream for longer than most HIV drugs. The BREATHER
trial tested whether or not young people could safely have a weekend break from taking their HIV
drugs if they took a combination containing efavirenz every weekday. Previous smaller studies in adults
investigating weekend breaks in HIV treatment showed that this was possibly a safe and effective strategy
in adults taking efavirenz. The BREATHER trial was designed to further test this strategy in a larger group
of children, adolescents and young adults. Participants were invited to join a substudy that, using in-depth
interviews, focused on the impact of the weekend breaks on their quality of life.
In total, 199 HIV-infected people aged 8–24 years from 11 countries participated. These participants were
already on HIV treatment and had very low virus levels in their blood. They were randomly (like tossing a
coin) divided into two groups, with half continuing daily drugs and half taking ‘short-cycle therapy’ (SCT),
which involved taking drugs for 5 days with 2 drug-free days each week (generally at weekends).
After 1 year, those in the SCT group were as likely to have their virus under control as those taking drugs
every day. Very few in either group had a substantial increase in HIV level (six in the SCT group and seven
in the continuous therapy group). There was no significant difference in side effects or drug resistance
between the groups.
With appropriate support, SCT may be an option for well-adherent older children, adolescents and young
adults on efavirenz. Follow-up will continue until mid-2016 to see whether or not SCT remains safe and
effective over the longer term.
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Scientific summary
Background
As the cohort of children with human immunodeficiency virus (HIV) infection in the UK and Ireland ages
(median age 5.1 years in 1996, increasing to 9.9 years in 2006 and 13.6 years in 2013), paediatricians face
new challenges in the management of HIV infection, including maintaining treatment adherence.
A range of available drugs is effective in blocking the replication of HIV. They are usually used in a
combination of three drugs (sometimes four) and are taken once or twice each day. This combination
antiretroviral therapy (ART), the standard of care for > 10 years, suppresses HIV, thus preventing decline in
immunological function and the development of associated opportunistic infections, all resulting in marked
reductions in morbidity and mortality in HIV-infected children. ART is expensive but is cost-effective (the
cheapest first-line regimen cost approximately £7000.00 per annum in 2008). However, there is increasing
recognition of the difficulties that young people face in maintaining long-term adherence to treatment
regimens. The critical importance of adherence to the long-term success of ART in maintaining virological
suppression and preventing the emergence of resistance has been established. However, experience with
HIV-infected young people suggests that, with current treatment strategies, adherence rates frequently fall
below the 90–95% adherence associated with long-term success. Furthermore, there is increasing
recognition of the long-term toxicities of some ART regimens [e.g. efavirenz (EFV)], which is particularly
relevant for young people facing lifetime ART, and the associated burden on the NHS.
There is a growing population of young people, pre-adolescents, adolescents and young adults, who face
the challenge of long-term adherence to daily ART and for whom better treatment approaches are
needed. One possible strategy, relevant for long-acting ART regimens, is to give therapy during the week
but allow a break at the weekend. The BREATHER trial aimed to show that, with an EFV-based ART
regimen, such a strategy could be effective in maintaining virological suppression, could counteract the
trend towards decline in adherence and, importantly, does not lead to an increase in resistance mutations.
Objectives
The primary objective was to determine whether or not EFV-based ART in short cycles of 5 days on and
2 days off (short-cycle therapy; SCT) was as efficacious (in maintaining virological suppression) as continuous
EFV-based ART (continuous therapy; CT) in HIV-infected young people aged 8–24 years. Secondary
objectives included the occurrence of new clinical HIV events or death, changes in immunological status,
emergence of HIV drug resistance, drug toxicity and changes in therapy.
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Participants
Inclusion criteria were:
l HIV-1-infected young people aged 8–24 years inclusive, with parents/carers and/or young people,
where applicable, willing to provide informed consent.
l On a stable first-line ART treatment regimen containing at least two nucleoside reverse transcriptase
inhibitors (NRTIs)/non-nucleoside reverse transcriptase inhibitor (NNRTIs) and EFV for at least 12 months
and willing to continue the regimen throughout the study period. Young people on regimens
containing nevirapine (NVP) or a boosted protease inhibitor (PI) with undetectable viral load (VL) for
> 1 year could be enrolled if they switched to EFV and remained stable with a VL of < 50 copies (twice)
for a minimum of 12 weeks. Previous dual therapy and/or substitution of NRTIs was allowed providing
any changes were not for disease progression or immunological or virological failure, defined as two
successive HIV-1 ribonucleic acid (RNA) results of > 1000 copies/ml, subsequent to virological control
having been achieved on ART.
l Viral suppression (HIV-1 RNA < 50 copies/ml) for at least the previous 12 months (at least the last three
measurements, including screening); young people who had experienced a single VL blip [> 50 but
< 1000 copies/ml (preceded and followed by a VL of < 50 copies/ml) in the last 12 months could
be enrolled].
l CD4 cell count of ≥ 350 × 106/l at the screening visit.
l Clinical centre needed to routinely use an assay that detected a HIV-1 RNA VL of ≥ 50 copies/ml.
Exclusion criteria were:
l pregnancy or risk of pregnancy in females of childbearing potential
l acute illness (young people may be enrolled after illness)
l receiving concomitant therapy for an acute illness (young people may be enrolled after recovery)
l creatinine, aspartate aminotransferase or alanine aminotransferase elevation of grade 3 or above
at screening
l on a regimen including NVP or a boosted PI drug (young people could substitute to an
EFV-based regimen)
l previous ART monotherapy (except for prevention of mother-to-child transmission).
Methods
Young people were randomised 1 : 1 to either remain on continuous ART or change strategy to a SCT
strategy of 5 days on ART and 2 days off.
The first 32 young people randomised were enrolled in an integral pilot study with additional monitoring
on a Monday morning (before taking ART) at weeks 1, 2, 3 and 4. The pilot study results were reviewed
by the Independent Data Monitoring Committee before young people were enrolled in the main trial.
The trial was managed by three Paediatric European Network for Treatment of AIDS (PENTA) trials units,
led by the Medical Research Council Clinical Trials Unit at University College London where data analyses
were undertaken. Data were recorded on case report forms and sent to the trials units, entered onto
databases and exported into Stata 13.1 (StataCorp LP, College Station, TX, USA) for analysis.
In the main trial, young people were monitored for a minimum of 48 weeks, with scheduled clinic visits at
4 and 12 weeks after randomisation and then every 12 weeks.
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The primary outcome (virological failure) was reached if a young person had a confirmed (i.e. twice) VL of
≥ 50 copies/ml. The difference between arms in the proportion of young people reaching the primary end
point was calculated at 48 weeks using Kaplan–Meier methods, adjusting for stratification factors (age
band; African vs. non-African). A 12% non-inferiority margin was prespecified, so that, if the upper bound
of the 90% confidence interval (CI) of the difference in proportion (CT – SCT) was < 0.12, non-inferiority
would be demonstrated.
Secondary end points included the occurrence of new HIV Centers for Disease Control (CDC) B or C events
or death, a HIV-1 RNA VL of < 50 copies/ml at 24 and 48 weeks, changes in CD4 count and CD4%,
emergence of major resistance mutations, evidence of drug toxicity and changes in ART.
Results
In total, 199 young people were enrolled between 1 April 2011 and 28 June 2013. Participants were
followed up for a median of 85.7 weeks up to 22 August 2014.
Baseline characteristics
The 199 young people were randomised from 11 countries to SCT (n= 99) and CT (n= 100). In total,
105 (53%) participants were male and the median [interquartile range (IQR)] age of participants was 14.1
(11.9–17.6) years; 77 participants (39%) were aged 8–12 years, 80 (40%) were aged 13–17 years and
42 (21%) were aged 18–24 years. In total, 70 participants (35%) were recruited from a single centre in
Uganda. Overall, 56% of young people were black, 19% were Asian and 21% were Caucasian.
The median (IQR) CD4 count was 735 (575.5–967.5) cells/mm3 and the median (IQR) CD4% was 34.0%
(29.5–38.5%). There were more young people in the CT arm than in the SCT arm with CDC stage C
events at baseline (13 SCT vs. 21 CT). All other characteristics were well matched between arms.
All young people were on first-line ART, never having switched for virological failure, although some had
had previous regimen changes for simplification or toxicity. Thus, 88 (41%) young people were on their
exact initial ART regimen at baseline and 29 (15%) had had previous exposure to a PI.
Of 80 young people completing a baseline acceptability questionnaire, 70 (88%) thought that stopping
ART at the weekends would make life easier than CT.
Follow-up
At the end of the main trial, the median (IQR) follow-up time was 85.7 (62.0–118.3) weeks. One young
person was lost to follow-up by week 48 (moved to a different country after the week 24 visit). At least
93% of the young people attended every scheduled visit up to week 48.
Primary end point
By week 48, 13 young people reached the primary end point of HIV-1 RNA ≥ 50 copies/ml, six from the
SCT arm and seven from the CT arm. The estimated probability of virological failure in the SCT arm
was 6.1% and in the CT arm was 7.3%, an estimated difference (SCT –CT) of 1.2% in favour of SCT
(90% CI –7.3% to 4.9%). The upper bound of the 90% CI of the difference was 4.9%, well within the
non-inferiority margin of 12%. The results are consistent with the non-inferiority of SCT compared with CT.
The analysis was repeated without adjusting for stratification factors and results were qualitatively
unchanged (results not shown).
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Changes in antiretroviral therapy strategy during the trial
Eight young people on SCT changed strategy to taking drugs 7 days a week during the first 48 weeks:
six reached the primary end point, one discontinued EFV because of an adverse event (AE) and one who
remained virologically suppressed discontinued for compliance issues.
Adherence
It was important to measure adherence to the randomised arm to ensure that those randomised to SCT
stopped ART at weekends and those randomised to CT did not stop ART at weekends. We evaluated this
in four ways: self-reported adherence questionnaires; a MEMSCap™ Medication Event Monitoring System
(MEMSCap Inc., Durham, NC, USA) substudy in which number of MEMSCap openings were electronically
recorded; by investigating haematological mean corpuscular red blood cell volume (MCV) in those taking
zidovudine (ZDV) as part of their ART regimen (ZDV is associated with an increase in MCV levels with
increased exposure); and self-reported adherence questionnaires.
Analysis of questions on compliance to SCT strategy at follow-up visits showed good compliance, with
95% of weekend breaks being taken in the SCT arm (99% excluding time after return to CT). The
MEMSCap substudy was carried out in 61 young people (n= 31 SCT group, n= 30 CT group), of whom
46 (n= 23 SCT group, n= 23 CT group) continued to use MEMSCaps throughout the 48 weeks. The
median (IQR) number of bottle openings per week was 5 (4–5) for those on SCT compared with 7 (6–7)
for those in the CT arm. A significantly higher level of MCV was observed in ZDV recipients randomised
to SCT versus CT at each visit (p< 0.01); this difference was not observed in young people not on
ZDV-containing ART. Self-reported adherence was similar in both arms, with 7% (29/414) reports in the
SCT arm versus 10% (40/409) reports in the CT arm of missing ART in the last week (excluding weekend
breaks in SCT) (p= 0.42).
These four measurements provided strong supportive evidence that participants in each arm were
adherent to their randomised strategy as stated in the protocol.
Secondary end points
Of 13 young people (n= 6 SCT group, n= 7 CT group) reaching the primary end point, resistance results were
obtained from nine (n= 3 SCT group, n= 6 CT group); the remaining four had resistance tests performed but
the VL of the sample was too low to obtain a result. Seven young people (n= 2 SCT group, n= 5 CT group)
had major NNRTI mutations at virological failure. In the SCT arm these were L100I+ Y188C+K103N and
K103N and in the CT arm these were E138A+V106M, K103N+V106M, M230L, V106M+ K103N and
G190S. Two young people, one from each group, had the M184V NRTI mutation.
The primary analysis was repeated with the end point as a confirmed VL of ≥ 400 copies/ml. Six young
people reached this end point (n= 2 SCT group, n= 4 CT group); the results were consistent with the
non-inferiority of SCT.
There were no significant differences between arms in immunological markers (CD4 count, CD4%, CD3
count, CD3%, CD8 count or CD8%). No significant differences were observed between arms with regard
to biochemistry, haematology or lipid markers.
Of 90 young people randomised to SCT who completed the end-of-study acceptability questionnaire
(completed at the last follow-up visit or at the time of change to CT), 81 (90%) reported that weekend
breaks made life a little or a lot easier. The main benefit was going out with friends, which 15 out of 76
young people said was difficult at baseline compared with only two out of 76 at study end (p= 0.001).
Safety
There were no new CDC stage C events or deaths and only two CDC stage B events, one in each group.
There were 13 serious adverse events in nine young people, seven episodes in six young people in the SCT
arm and six episodes in three young people in the CT arm. There were no significant differences between
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arms in grade 3 or 4 AEs or treatment-modifying AEs. However, the CT arm had more ART-related AEs
(two episodes in two young people on SCT vs. 14 episodes in 10 young people on CT) (Poisson p= 0.02
for difference in event rates).
Qualitative substudy results
In the qualitative interviews, participants from both arms discussed their initial anxieties about the impact
of SCT on their health and adherence patterns; these anxieties decreased over the early months in the trial.
Those randomised to SCT reported an overall preference for SCT over CT pre trial. However, despite
overall positive experiences on SCT, young people reported challenges adapting to SCT in the short term.
Once they had adapted to the new routine, SCT was reported to reduce the impact of side effects and the
pressure to carry and remember medication, thus enabling more weekend activities. Attitudes to SCT did
not vary greatly by gender, route of transmission or country. Participants from both arms reported frequent
(not easily quantifiable) central nervous system side effects attributed to EFV, and occasional missed doses,
which had been difficult to voice to clinic staff. SCT has the potential to encourage more candid
discussions about adherence ‘slippages’ and how treatment demands can be managed alongside their
other priorities. Although participants liked SCT by the trial end, they had concerns that peers who had the
most problems adhering would also have the most difficulties with managing SCT, with it potentially being
disruptive and leading to longer ‘slippages’. To realise the potential of SCT and mitigate possible risks,
careful dissemination and communication post trial is needed. SCT should be provided as part of a
package of monitoring, support and education over 3 months to allow adaptation.
Conclusions
In the BREATHER (PENTA 16) trial after 48 weeks of follow-up, 94% young people remained virologically
suppressed and the non-inferiority of SCT compared with CT was demonstrated with only a 1.2% difference
in viral suppression to < 50 copies/ml between the arms, in favour of SCT. Primary and secondary analyses
were consistent with no significant differences in the secondary end points. Safety profiles were similar
between the two strategies, except that there were more ART-related AEs reported in the CT arm.
Acceptability questionnaires indicated a strong preference for the SCT strategy compared with CT.
In this Phase II study, the non-inferiority of SCT compared with CT was demonstrated in a select group of
virally suppressed, adherent young people on first-line EFV-based ART. These results offer proof of concept
that SCT, using at least one antiretroviral (ARV) with a long half-life, can be as effective as daily therapy,
resulting in less restriction at weekends and normalising life experiences for young people while reducing
overall drug exposure.
A 27% reduction in ARVs needed to maintain viral suppression also has potentially significant cost savings,
which might eventually enable even more young people to receive therapy in resource-limited areas.
Importantly, before such a strategy can be more widely adopted, the Trial Management Group, the Trial
Steering Committee and the Independent Data Monitoring Committee agreed that review of the results
over a longer period of follow-up was required. This has received approval from all ethics committees
and is currently under way. In total, 176 out of 194 (90.7%) young people agreed to continue their
randomised strategy with follow-up to July 2016. In addition, studies in broader patient populations, with
different monitoring strategies and for longer durations, will be required before considering SCT strategies
in clinical practice guidelines.
The BREATHER trial was presented as an oral late-breaker presentation at the Conference for Retroviruses
and Opportunistic Infections meeting in Seattle, USA, in February 2015. Information has been disseminated
to all of the clinical centres participating in the trial, including an information leaflet for young people.
The main trial results have been published in The Lancet [The BREATHER (PENTA 16) Trial Group.
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young
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adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial (published online ahead of
print 20 June 2016). Lancet HIV 2016].
Trial registration
This trial is registered as ISRCTN97755073, EUDRACT 2009–012947–40 and CTA 27505/0005/001–0001.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research (projects 08/53/25 and 11/136/108), the European Commission through
EuroCoord (FP7/2007/2015), the Economic and Social Research Council, the PENTA Foundation,
the Medical Research Council and INSERM SC10-US19, France.
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Chapter 1 Introduction
Antiretroviral therapy (ART) has dramatically improved the prognosis for human immunodeficiency virus(HIV)-infected children. It has reduced early morbidity and increased survival, with > 80% of children
expected to reach adulthood.1 HIV infection has been transformed from a devastating, rapidly progressive
lethal condition into a chronic disease. Now the challenges for the treatment of HIV-infected children are
to (1) maximise the benefit of ART, which prevents illness and encourages growth and development,
(2) minimise long-term drug toxicity, (3) minimise the development of drug resistance so that children
continue to have therapy options as they move through adolescence and into adulthood, and (4) improve
quality of life as much as possible for young people on ART.
Following recent results from a randomised controlled trial, in 2008 paediatric ART guidelines advocated
starting ART in infancy (< 12 months of age) in all those diagnosed, because of a high risk of disease
progression.2 Subsequent guidelines from the World Health Organization (particularly for African countries)
recommended starting ART in all children aged < 2 years (20103) and then in all children aged < 5 years
(20134), mainly for programmatic reasons. Even if ART is not started early, vertically infected children face
many more years of ART than adults, often given throughout childhood. Therefore, there is a growing
population of older children and young people who have already been on ART for many years and are
continuing to face the challenge of taking daily medication.5
A major challenge for young people with HIV infection, as for any chronic illness, is maintaining long-term
adherence to treatment regimens.6–8 The importance of adherence to the long-term success of ART in
maintaining virological suppression and preventing the emergence of resistance has been established.9–16
However, experience with HIV-infected young people suggests that, with current treatment strategies,
adherence rates fall far below the 90–95% adherence associated with long-term success.17–19 Furthermore
some studies have demonstrated a decline in adolescent adherence over time associated with duration on
therapy.19 Impediments to adherence for young people have been broadly categorised into two main
groups: problems with medication, such as taste and palatability issues, and adherence difficulties related
to social situations.20 Although there have been considerable attempts to improve drug formulations, thus
partly addressing the first impediment, the social dimensions are more complex; interference with daily life
recurs as a common theme in assessments of poor adherence in young people.
New treatment strategies that promote adherence, minimise the development of resistance and reduce
long-term drug exposure while improving quality of life are required for young people ‘burning out’ on
daily ART regimens. Approaches to achieve this include (1) simplification of therapy (i.e. minimising the
number of pills or swapping from twice-daily to once-daily dosing), (2) treatment interruptions [e.g. based
on levels of CD4 as in the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial;21 not
currently advocated] and (3) very short treatment interruptions (particularly at inconvenient times for taking
medication such as weekends) with the aim of maintaining viral suppression (one such possible strategy is
to give therapy during the week but allow a break at the weekend).
Intermittent therapy
CD4-guided treatment interruptions
The large Phase III Strategies for Management of Antiretroviral Therapy (SMART) trial evaluating a
CD4-guided strategy in adults of stopping ART when the CD4 count was > 350 cells/mm3 and restarting
ART when the CD4 count fell to < 250 cells/mm3 was stopped early because of evidence of increased
disease progression and cardiovascular events, albeit at low rates, in the interruption arm.22 Treatment
interruption when viral load (VL) rebound occurs is now not recommended in adults.
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The PENTA 11 Phase II trial [a randomised trial that compared CD4-guided planned treatment interruptions
with continuous therapy (CT) in children aged 2–15 years] reported no significant increase in clinical
progression in children undergoing planned treatment interruptions.21 Further data on CD4 recovery and
VL suppression following reintroduction of continuous ART in all children in this trial are awaited and
interruptions using this strategy cannot be currently recommended. However, the initial findings of PENTA
11 provided reassurance for two other paediatric trials to investigate the impact of treatment interruptions
{one evaluating interruptions following early limited ART in infants23 and the other evaluating CD4-guided
interruptions in 600 older children [the BANA II trial; see www.bipai.org/Botswana/clinical-research.aspx
(accessed 6 April 2016)]}.
Fixed-length treatment interruptions
In adults, trials of a fixed-length ART schedule of 1 week on and 1 week off therapy, based on the theory
of autoimmunisation,24 showed high virological failure rates in patients following the 1 week on and
1 week off strategy compared with those on continuous or CD4-guided ART.25,26
Very short treatment interruptions
An alternative approach is to use very short interruptions (short-cycle therapy; SCT) such that viral rebound
should not occur, thus minimising the emergence of resistance as well as not compromising antiviral
efficacy. This concept is based on the notion that > 95% adherence may not be necessary for virological
suppression with all antiretroviral (ARV) regimens and that each ARV combination may have a unique
adherence–resistance relationship.9 Mathematical models of adherence and the emergence of resistance
support this and the notion that otherwise strongly adherent patients might miss an acceptable number of
doses of selected ARVs before resistance emerges.27
Short-cycle therapy in adults and adolescents
Two Phase II trials of SCT in adults reported before the start of the BREATHER trial. First, a small single-arm
pilot study of 5 days on, 2 days off ART in adults in the USA showed that long-term suppression of VL
could be achieved.28 Two of nine patients on protease inhibitor (PI)-based highly active antiretroviral
therapy (HAART) had confirmed virological rebound by 48 weeks compared with one of 10 patients on
nevirapine (NVP)-containing HAART and none of eight patients receiving efavirenz (EFV)-based regimens.
As a result of this pilot, the randomised FOTO (Five On Two Off) trial in 60 adults with a VL of < 50 copies/ml
on tenofovir (TDF)/emtricitabine (FTC)/EFV was conducted comparing daily ART with a strategy of 5 days
on, 2 days off treatment. The 24-week results showed that all 25 patients in the FOTO arm and 24 of
28 patients (86%) in the daily arm who reached week 24 had a VL of < 50 copies/ml at this time point.29
Reasons for not reaching 24 weeks were psychological (n= 2), because of the time burden (FOTO arm)
(n= 3), pregnancy (n= 1) and loss to follow-up (daily ART arm) (n= 1); of note, all had a VL of < 50 copies/ml
at discontinuation. There were six blips (VL 50–500 copies/ml) in the FOTO arm and nine in the daily ART arm
to week 24; there were no instances of virological failure (confirmed VL > 400 copies/ml).
Second, in a trial in Uganda,30,31 146 adults who had a suppressed VL of < 50 copies/ml on a three-drug
ART regimen were randomised to receive a week on, week off ART regimen (n= 32; this arm of the study
was discontinued early), a 5 days on, 2 days off schedule (SCT) (n= 57) or CT (n= 57). The majority of
subjects (94%) received an EFV-based regimen. The trial showed that SCT was not inferior to continuous
HAART; there were 11 cases of failure in the CT group (including one death) and six in the SCT group
(failure defined as VL > 1000 copies/ml, a decrease in CD4 count from randomisation of > 30% or a CD4
count of < 100 cells/mm3 on two consecutive occasions through the 72 weeks of follow-up; or VL
> 400 copies/ml or development of an opportunistic infection at 72 weeks). Levels of resistance were no
different between the SCT group and the CT group. For patients on HAART containing stavudine, there
was a significant decrease in the incidence of lactic acidosis in the SCT arm compared with the CT arm.
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The US-based Adolescent Trials Network conducted the only study of SCT in adolescents prior to the
BREATHER trial, which had a non-randomised single-arm design to assess VL suppression (< 400 copies/ml,
confirmed) on SCT (4 days on HAART, 3 days off) over 48 weeks.32 Thirty-two participants aged 12–24 years
and on a stable PI-based HAART regimen for at least 12 months were enrolled. Twelve of the 32 (38%)
participants had confirmed virological rebound by 48 weeks, seven out of 15 (47%) of those infected
before 9 years of age and five out of 17 (29%) of those infected after 9 years of age (p= 0.5). However,
75% of children had been exposed to five or more drugs in the past, with a previous history of virological
failure. Overall, adherence was good (88% of participants showed > 90% adherence), with no difference
between those with and those without VL rebound (p= 0.6).
Antiretroviral agents, viral load rebound and resistance
The plasma half-life of ARV agents in an ART regimen [or intracellular half-life of nucleoside reverse
transcriptase inhibitor (NRTIs)] and their genetic barrier to resistance are important factors that may
influence VL rebound and the development of resistance during a strategy of stopping therapy for 2 days
every week.
An ART regimen containing three drugs, with relatively similar long half-lives and maintained therapeutic
concentrations of > 2 days when treatment is stopped, would be an ideal regimen to avoid risk of VL
rebound during the interruption and minimise the development of resistance. The regimen with the most
favourable pharmacokinetic profile is TDF/FTC/EFV (median intracellular half-life of 150 hours, median
intracellular half-life of 39 hours and plasma half-life of between 36 and 100 hours, respectively).33
Coformulation of TDF/FTC/EFV34 in a single pill makes this a very attractive combination for older adolescents
and young adults. However, in the Ugandan trial,31 EFV was given with either stavudine/lamivudine (3TC) or
zidovudine (ZDV)/3TC without evidence of inferior virological performance, even though stavudine, 3TC and
ZDV have shorter half-lives than TDF and FTC. PI drugs [e.g. lopinavir/ritonavir (Kaletra®; AbbVie Inc.),
the most commonly used PI in children and adolescents] have substantially shorter half-lives and therefore
if a regimen containing two NRTIs (with longer half-lives) and a PI (with a shorter half-life) is stopped,
‘functional dual NRTI therapy’ may result, with a risk of VL rebound and the development of resistance.
Data on viral dynamics in the first few days following treatment cessation are scarce. Jacobsen et al.,24
in a four-arm study of planned treatment interruption±HIV immunisation, reported viral rebound to
> 50 copies/ml following treatment interruption at a median [interquartile range (IQR)] of 15 (8–31) days
for those with a prior planned treatment interruption and 21 (13–30) days for those without a prior
planned treatment interruption. Harrigan et al.,35 while assuming a constant rate of viral increase that
starts as soon as the patient stops therapy, suggest that many patients stopping therapy (previously
suppressed) will have an increase in plasma viral HIV ribonucleic acid (RNA) of about 0.2 log/day and will
reach detectable levels (> 50 copies/ml) only within 1–2 weeks of stopping therapy.
A substudy of PENTA 11 evaluated the pharmacokinetics, VL rebound and resistance profiles in 35 children
stopping non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART.36 In total, 21 children followed
a staggered stop strategy whereby the NNRTI (NVP or EFV) was stopped at randomisation and the
remaining two NRTI drugs were stopped 7–14 days later, and 14 children followed a replacement strategy
whereby the NNRTI was replaced with a PI and all drugs were stopped 7–14 days later. Results of HIV VL
testing in eight children following the staggered stop strategy and seven children following the
replacement strategy showed that the majority of children still had undetectable HIV RNA 5–8 days after
stopping all drugs (minimum 12 days after stopping the NNRTI). No NNRTI resistance mutations were
detected in any of the children in the substudy.
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Rationale and objectives
Adherence issues tend to worsen for older children and adolescents after they start taking charge of their own
medication (after HIV diagnosis is disclosed); self-consciousness and not wanting to be different from peers
predominate. There is the additional burden of secrecy around HIV infection and ART,15 and social and family
pressures prevent young people from sharing information of their diagnosis or treatment with friends.37
The result is often worsening adherence with frequently missed doses, particularly at weekends, which are
typically times of socialising. Factors contributing to this include alcohol ingestion19 as well as the absence of
school and overnight stays with friends at weekends. Therefore, a regimen in which ARVs need be taken only
as part of the daily routine during weekdays could be attractive for older children (> 8 years) as well as
teenagers and young people (16–24 years) who continue to be followed at paediatric or affiliated
adolescent units.
Data from adult studies evaluating the strategy of 5 days on, 2 days off were promising, with low rates of
virological rebound seen. However, no randomised trial had been undertaken in older children and
adolescents, a population with potentially more to gain in terms of quality of life, long-term adherence to
medication and the potential for better treatment options in adulthood. The effect on overall adherence of
allowing 2 days off treatment per week was unknown and it was therefore important to first evaluate the
strategy in young people who have a history of good adherence, the argument being that offering this
strategy could prevent ad hoc missed doses occurring. In view of the relatively shorter half-life of PIs and
because both adult trials referred to above were undertaken with EFV-based regimens, enrolment was
limited to children who are on, or who are willing to switch to, a regimen containing EFV.
The BREATHER trial aimed to assess whether or not young people with chronic HIV infection undergoing
SCT of 5 days on and 2 days off following complete virological response to first-line ART for at least
12 months maintained the same level of VL suppression as those on CT. Importantly, because of
insufficient data on short-term VL rebound after stopping ART in this population, the trial incorporated an
initial pilot phase to assess the safety of the SCT strategy.
Risks and benefits
The potential risks of the SCT strategy were as follows:
l The main risk was that the SCT strategy would prove ineffective at maintaining VL suppression, either
because VL could not be maintained below detection levels during 2 days off ART or because of
non-adherence to the strategy by extending the time off treatment. However, if a raised VL was
confirmed on repeat testing (carried out within 1 week) then the participant was placed back on CT.
l An additional risk was that young people who had been fully adherent to ART before enrolment in the
study might extend the permitted very short interruptions and that overall adherence would decline.
Of note, there was equipoise about whether adherence would be better or worse in the SCT arm than
in the CT arm as young people in the continuous arm may also not take their treatment regularly.
All young people were given a diary to record when they had taken ART and were asked to comment
about difficulties in remembering to take medication. Rebounding VL comes with the risk of
development of resistance (particularly to EFV and 3TC, which have low genetic barriers to resistance),
which in turn may limit future therapeutic options. Resistance testing was performed on all young
people who lost virological suppression in either arm at the point of loss of suppression (≥ 50 copies/ml),
as well as on any subsequent samples with a HIV-1 RNA level of ≥ 1000 copies/ml.
INTRODUCTION
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The potential benefits of the SCT strategy were:
l improvement in quality of life from having weekends free from taking medication
l improved long-term adherence during the week
l decreased long-term toxicity of ARV drugs (particularly relevant for some NRTI drugs, e.g. ZDV and TDF)
l decreased cost, which is important to any health-care service and in particular for many parts of the
world where HIV prevalence is highest.
Young people and carers were fully informed of the possible benefits and known risks by means of a
patient information sheet as appropriate and this was reinforced by discussions with the study research
teams at the individual sites prior to enrolment.
Pilot study
Because of insufficient data on short-term VL rebound after stopping ART in this population, the trial
incorporated an initial pilot phase in selected centres. The aim of the pilot phase was to ensure that the
SCT strategy did not result in a high proportion of young people with an increased VL (≥ 50 copies/ml) of
ART in the first few weeks.
Those enrolled in the pilot and randomised to SCT were permitted to take only Saturday and Sunday off
treatment. They received VL testing on Monday, prior to resumption of ART. Recruitment to the main trial
commenced only when all pilot participants had completed 3 weeks on the study and the results were
reviewed by the Independent Data Monitoring Committee (IDMC) to ensure that there were no safety
concerns. Preset criteria for stopping included a HIV-1 RNA level of ≥ 50 copies/ml (validated by a HIV-1
RNA level of ≥ 50 copies/ml on the same sample) at weeks 1, 2 or 3 following weekend interruption and
before restarting ART in more than five participants as this would have given evidence that VL suppression
rates on a SCT strategy in general were < 90% [10/15 suppressed= 66%, 95% exact confidence interval
(CI) 38% to 88%]. Data from the pilot phase were reviewed by the IDMC who identified no safety
concerns and recommended that recruitment continue.
Substudies
Plasma and cells were stored for both arms throughout the trial for the virology, inflammatory biomarkers
and immunology substudies. The rationale behind the biomarker substudy was to determine whether or
not any markers of inflammatory response were increased among children in the SCT arm compared with
the CT arm, even if VL suppression was no different. This has been observed in adult trials such as the
SMART trial in which interruptions resulted in an increase in VL.22
There was also a qualitative substudy that aimed to (1) evaluate the acceptability of SCT and of the trial
from the perspectives of young people participating; (2) explore whether or not they perceived that
SCT facilitated improved adherence; (3) document how young people experience life with ART; and
(4) understand how their experiences in adolescence affect their capacity and willingness to adhere to
taking their treatment. As well as producing knowledge to better support optimum adherence among
adolescents, the study also aimed to (5) compare the HIV treatment and trial experiences of young people
in the UK, Ireland, Uganda and the USA.
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Chapter 2 Methods
This open, randomised, parallel-group Phase II/III trial was performed in 24 centres worldwide(see Acknowledgements for the different sites). This was a strategy trial.
Trial entry criteria
The trial enrolled HIV-1-infected young people aged 8–24 years inclusive who had been on a stable
first-line ART treatment containing at least two NRTIs/NNRTIs and EFV for at least 12 months and who
were willing to continue the regimen throughout the study period. Previous dual therapy and/or
substitution of NRTIs was allowed providing any changes were not the result of disease progression or
immunological or virological failure (with virological failure defined as two successive HIV-1 RNA results of
> 1000 copies/ml) subsequent to virological control having been achieved on ART. They must have had
viral suppression (HIV-1 RNA < 50 copies/ml) for at least the previous 12 months (at least the last three
measurements, including screening). Young people who had experienced a single VL of > 50 copies/ml but
< 1000 copies/ml (preceded and followed by a VL of < 50 copies/ml) in the last 12 months could be
enrolled. They must have had a CD4 cell count of ≥ 350 × 106/l at the screening visit.
Exclusion criteria were pregnancy or risk of pregnancy in females of childbearing potential, acute illness,
receiving concomitant therapy for an acute illness or a creatinine, aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) elevation of grade 3 or above at screening. Participants could not be on a
regimen including NVP or a boosted PI (young people could be switched to an EFV-based regimen) or have
had previous ART monotherapy (except for the prevention of mother-to-child transmission).
The age group of 8–24 years was chosen as young people between these ages are likely to undertake
independent weekend activities and thus SCT could improve their quality of life by giving them more
control over when they take their HIV medication, helping them to maintain their privacy regarding HIV
infection and treatment taking while socialising at weekends.
Randomisation and treatment strategies
Participants were randomly assigned 1 : 1 to maintain CT or switch to SCT. Randomisation was performed
centrally by the Medical Research Council Clinical Trials Unit (MRC CTU) at University College London
(UCL) according to a computer-generated randomisation list, using random permuted blocks stratified by
age at randomisation (8–12, 13–17 and 18–24 years) and by African compared with non-African country.
The trial sites enrolled patients and assigned participants to interventions by either accessing the trial
randomisation server directly or contacting the relevant trial unit who performed the randomisation on
their behalf.
Young people randomised to SCT followed a cycle of 5 days on ART (Monday–Friday or Sunday–Thursday)
and 2 days off (Saturday and Sunday or Friday and Saturday). Participants randomised to the SCT arm
were able to choose which 2 days off ART they preferred and whichever days were chosen were continued
throughout the entire time on SCT within the study. Young people randomised to CT continued their
current ART regimen and stopped or switched drugs in their ART regimen only for virological,
immunological or clinical failure according to local practice. However, if simplification of the ART regimen
or substitution of one drug (not EFV) was deemed necessary for clinical reasons, this was allowed after
discussion with the appropriate trials unit.
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Clinical examinations
A clinical examination was performed at screening, randomisation and certain follow-up protocol visits.
At each visit the following data were recorded: body weight and height and all adverse events (AEs) since
the last protocol visit, including in particular haematological abnormalities, pancreatitis, diarrhoea, clinical
lipodystrophy, acute illnesses and change in HIV disease stage since the last protocol visit.
A physician assessment of lipodystrophy and Tanner stage was performed at week 0 and repeated every
24 weeks until the end of the study. A pregnancy test was performed for all females of childbearing
potential at screening (weeks –4 to –2) and repeated every 24 weeks until the end of the trial and at other
time points if required.
Ethnic-origin data were collected because it is known that ethnicity is a factor in the concentration levels
of EFV.
Laboratory tests for efficacy and safety monitoring
l Haematology: haemoglobin, mean corpuscular red blood cell volume (MCV), platelets, white cell count,
neutrophil and lymphocyte counts.
l Biochemistry: creatinine, albumin, total bilirubin, ALT, AST, alkaline phosphatase, calcium, phosphate.
l Lipids/glucose: triglycerides, cholesterol [total, low-density lipoprotein (LDL), high-density lipoprotein,
very-low-density lipoprotein], glucose (participants should have been fasting overnight at
randomisation, weeks 24 and 48 and then every 48 weeks during the main trial).
l Lymphocyte subsets: CD3 (absolute and percentage), CD3+CD4 (absolute and percentage*),
CD3+CD8 (absolute and percentage*), total lymphocyte count (if measured by immunology
laboratory) (*CD45RO/RA if measured).
l Virology: HIV-1 RNA (VL) using an ultrasensitive assay and resistance testing [locally or on stored
samples (when VL was detectable)].
Screening visit
At the screening visit a trial number was assigned and used on all paperwork and labels. A clinical
assessment was completed and the participant and/or carer completed an adherence questionnaire
according to the young person’s age and knowledge of HIV diagnosis.
Blood was taken for haematological and biochemical investigations, for measurement of T-cell subsets
(including RO/RA phenotype when available), for measurement of HIV-1 RNA VL (it was requested to use
the same assay at least throughout the pilot phase and ideally throughout the whole trial, although the
assays used varied across centres according to clinical practice and management) and for plasma and cell
storage (at clinical centres where this was possible).
Randomisation visit
Randomisation (week 0) took place no more than 4 weeks after the screening visit and ideally as soon as
possible after eligibility had been confirmed. The eligibility criteria and consent were reconfirmed verbally
and noted on the randomisation form. Once a patient was randomised, a clinical assessment was
completed, which included measurements of height and weight, presence of AEs, change in HIV disease
stage and ethnic origin. The following investigations were performed: haematology, biochemistry, glucose
and lipid profiles (fasting) and T-cell subsets (plus RO/RA phenotype if available). Blood was taken for
plasma storage (plus cell storage if the participant attended a clinical centre where this procedure was
possible or where a courier could be arranged). A quality-of-life questionnaire [Pediatric Quality of Life
Inventory; see www.pedsql.org/ (accessed 6 April 2016)] was completed for all participants (and carers)
and an acceptability questionnaire was completed for those young people randomised to SCT
(and carers). Participants were given a diary to record when they took their ART, which included a
reminder to restart therapy after the 2 days off ART in the SCT arm.
METHODS
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Follow-up
Young people were followed until the last randomised participant had completed 48 weeks of follow-up.
All young people were seen for clinic visits at weeks –4 to –2 (screening), 0 (randomisation), 4, 12, 24, 36
and 48.
Sample size
This trial planned to enrol a minimum of 160 young people, at least 80 per arm.
Assuming that 90% of young people in the CT arm and in the SCT arm maintained a HIV-1 RNA level of
< 50 copies/ml to week 48, 155 young people would have provided at least 80% power to exclude a
difference of 12% between the two arms (i.e. to exclude suppression rates of < 78% in the SCT arm)
(one-sided alpha= 0.05).38 A minimum of 160 young people (80 per arm) had to be enrolled to allow for
loss to follow-up (in previous PENTA trials loss to follow-up has been < 3%).
The power calculations were based on the assumption that 90% of patients in the CT arm would remain
virally suppressed to week 48. Any decrease in this percentage was likely to underpower the study and
would lead to an equivocal result, as could other changes to the assumptions.
A sample size of 220 participants would have increased the power of the study by at least 10% for varying
levels of suppression. At its meeting in December 2012, the Trial Steering Committee (TSC) recommended
that the study should remain open to randomisation until the end of the defined recruitment period, even
if the total number of participants enrolled exceeded 160, as this would enhance the power of the study;
this was communicated to and agreed by the IDMC. The specified sample size was increased in protocol
version 1.7 (dated 24 April 2013) from a recruitment target of 160 to a target of at least 160 but not
exceeding 220 participants (see Appendix 1).
The trial was not formally powered to detect differences between CT and SCT, but to exclude substantial
virological disadvantages [i.e. HIV-1 RNA suppression rates (< 50 copies/ml) of < 78%] in the SCT arm by
following a 5 days on, 2 day off strategy, that is, a non-inferiority trial.
A non-inferiority margin of 12% was chosen to represent a clinically acceptable difference in the rate of
virological suppression (HIV-1 RNA < 50 copies/ml) between the two arms and to allow the trial to be
adequately powered and feasible to conduct based on estimates of available young people followed in
PENTA centres.
Pilot study
The first participants randomised in the study (n= 15 in the SCT arm and n= 17 in the CT arm) were
included in the pilot phase and had weekly HIV-1 RNA measurements during the first 3 weeks of the
study. Those randomised to the SCT arm and included in the pilot phase stopped taking their ART on
Saturdays and Sundays, that is, they followed a cycle of 5 days on ART (Monday–Friday) and 2 days off
ART (Saturday–Sunday) during the pilot phase. Recruitment to the CT arm ran concurrently.
Young people in the pilot phase had four additional phlebotomy visits (HIV-1 RNA and blood store only) at
weeks 1, 2, 3 and 8. For young people in the SCT arm the blood draws were on the Monday after the
first, second and third weekends off ART and before ART recommenced; for young people in the CT arm
these blood draws were at any time during the first, second and third weeks.
The IDMC met at the end of the pilot phase to review the interim data (see Appendix 2 for dates of all
IDMC meetings).
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Management of young people and viral load tests
l Pilot phase. Polymerase chain reaction (PCR) tests for HIV-1 RNA can occasionally yield spurious results
suggestive of low-level viraemia. During the pilot phase only, any HIV-1 RNA measurement detected of
≥ 50 copies/ml at weeks 1, 2 or 3 was repeated on the same sample to ensure that the result was valid
and reproducible.
l SCT arm. Participants with a HIV-1 RNA measurement of ≥ 50 copies/ml had a confirmatory VL
measurement taken on a separate sample within 1 week. No further interruptions to ART were
undertaken until the repeat test result was obtained. Participants with a confirmed viral rebound of
≥ 50 copies/ml recommenced CT and should not have undergone further interruptions to their therapy.
Participants with an isolated HIV-1 RNA measurement of ≥ 50 copies/ml and a subsequent
measurement of < 50 copies/ml could remain on SCT. There could be a maximum of three such
occurrences during the lifetime of the study. After the third increase, CT was resumed with no
further interruptions.
l CT arm. Participants with a HIV-1 RNA measurement of ≥ 50 copies/ml had a confirmatory VL
measurement taken on a separate sample within 1 week. Participants with a confirmed VL of
≥ 50 copies/ml received standard clinical care.
Study duration
Young people were followed until the last randomised participant had completed 48 weeks of follow-up,
at which point the main trial was considered complete. Participants who were followed after week 48
were seen every 12 weeks until the main trial was complete. Participants randomised to the SCT arm
continued to follow the SCT strategy until the main trial was complete unless the clinician or the family
had concerns, which the clinician discussed with the appropriate trials unit.
Following the recommendations of the TSC (December 2013) and the subsequent protocol amendment
(version 1.9) and participant consent, ongoing long-term follow-up of the trial for a further 2 years
commenced in July 2014 (see Appendix 1). Stable and virologically suppressed young people who were
randomised to SCT can opt to continue SCT during the long-term follow-up if they have 12- to 16-week
VL monitoring and if agreed by the clinician and family. Management of HIV-1 RNA VL will continue as
during the main study period.
Data collection and handling
Sites in the UK and Ireland were managed by the MRC CTU, subsequently the MRC CTU at UCL. Sites in
the USA, Germany, Uganda, Thailand (HIV Netherlands Australia Thailand Research Collaboration) and the
Ukraine were managed by the MRC CTU at UCL in collaboration with national co-ordinators. Sites in Spain,
Belgium, Denmark and Argentina are managed by the French National Institute for Health and Medical
Research (INSERM SC10-US19) in collaboration with national co-ordinators. Program for HIV Prevention and
Treatment (PHPT) sites in Thailand were managed directly by the PHPT.
Data were recorded on case report forms (CRFs); the completed CRFs were sent to the appropriate trials
unit for data entry and a copy kept at the local clinical centre. Data from the CRFs were entered onto
databases held at the co-ordinating trials units and exported into Stata 13.1 (StataCorp LP, College
Station, TX, USA) for analysis. After completion, adherence and acceptability questionnaires were sent to
the appropriate trials unit for data entry.
METHODS
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Data received at each of the trials units were checked for missing or unusual values (range checks) and for
consistency within participants over time. If any such problems were identified, a missing data report of the
problematic data was sent to the local site by password-protected e-mail for checking and confirmation or
correction, as appropriate; any data that were changed were crossed through with a single line and
initialled. The amended data were returned to the appropriate trials unit and filed in the notes at the site.
The trials units sent reminders to sites under their management for any overdue and missing data.
Interim analysis
The trial was reviewed by the PENTA IDMC. No member of the PENTA Steering Committee or the BREATHER
TSC or any clinician (investigator) responsible for the clinical care of trial participants could be a member of the
IDMC. The IDMC reviewed all aspects of the trial, including the number of participants recruited.
The IDMC met four times in strict confidence over the course of the trial: 28 October 2011, 5 September
2012, 31 July 2013 and 7 February 2014, with the last meeting being about VL monitoring only. The
IDMC was to inform the chairperson of the TSC if, in its view, the results provided either:
(a) unequivocal evidence* that was likely to convince a broad range of HIV clinicians, including the study
investigators, that one of the two treatment strategies (CT or SCT) was performing poorly for all
participants or for a particular category of participants and there was a reasonable expectation that
this new evidence would materially influence patient management or
(b) good evidence* that CT was superior to SCT in terms of the primary outcome and the non-inferiority
of SCT was extremely unlikely to be demonstrated with continued enrolment and/or follow-up.
*The criteria for the strength of evidence could not be defined precisely and were left to the judgement of
the IDMC. However, as an example, if in an interim analysis the 99% CI for the hazard ratio for the
primary outcome excluded 1, this may be considered as providing good evidence of a difference in risk
between the two groups. If the 99.9% CI also excluded 1, this may be regarded as providing unequivocal
evidence of a difference between the two groups.
Clinical site monitoring
Trial-related monitoring at trial sites was carried out according to the trial protocol. Trial sites had to agree
to provide access to source data/documents. Consent from parents/carers/young people, as appropriate,
for direct access to data was also obtained.
In addition to a site initiation (either through a visit or in a teleconference), all clinical centres were
monitored at least once during the trial and the following data were validated from source documents:
l eligibility and signed consent
l clinical disease progression to new Centers for Disease Control (CDC) C event or death
l HIV-1 RNA VLs ≥ 50 copies/ml (primary end point only)
l a random sample of CD4 measurements
l a random sample of laboratory results
l a random sample of original records of ARV prescriptions (with batch numbers)
l a random sample of clinical data
l all original records of ARV prescriptions (with batch numbers) for all young people participating in the
qualitative substudy.
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Patient and public involvement
Polly Clayden, a patient advocate, has been an independent member of the PENTA Steering Committee for
many years and was closely involved in the discussions about the protocol during its development. She works
at i-Base, a treatment activist group, which is developing a young person Community Advisory Committee
with the UK Children’s HIV Association (CHIVA). Members of the study team, particularly in the UK and
Ireland, are closely involved with CHIVA, which promotes issues relevant to children infected or affected by
HIV, including the needs of adolescents and good practice in transitional care. Collaborator Magda Conway
is an independent consultant with extensive experience of working directly with young people with HIV.
She has been awarded a grant by the Elton John AIDS (acquired immunodeficiency syndrome) Foundation to
strengthen networks of young people living with HIV in the UK and facilitated a group discussion with MRC
CTU staff and a CHIVA youth group prior to the finalisation of the study protocol. CHIVA was closely
involved in developing a communication and dissemination strategy for the main trial results and created a
one-page results information leaflet (see Appendix 3) that was sent out to sites to give to their patients.
Protocol changes
See Appendix 1.
Main study statistical methods
Primary end point
The primary analysis was performed on the intention-to-treat population. We used Kaplan–Meier
techniques to estimate the proportion of young people failing in each arm by the 48-week assessment,
adjusting for stratification factors: age range (8–12, 13–17 and 18–24 years) and recruitment from an
African site. Using these proportions, we were able to estimate the difference in the proportion failing
between arms and obtain a 90% CI around the difference, using bootstrap standard errors. This CI was
used as an indicator of whether or not the results were consistent with the non-inferiority of SCT
compared with CT. The non-inferiority margin was prespecified at 12% so that, if the upper bound of the
90% CI of the difference between arms (SCT –CT) was < 0.12, non-inferiority would be demonstrated.
The primary analysis was repeated but without adjusting for stratification factors. Additionally, an analysis
was performed investigating the crude proportion of young people who experienced virological failure up
to the end of the 48-week assessment.
Secondary end points
All analyses performed on the primary end point were repeated but instead considering the end point as a
confirmed VL of ≥ 400 copies/ml.
Immunology, biochemistry and lipids were evaluated at each follow-up visit up to 48 weeks after
randomisation by fitting normal regression models, adjusting for randomised arm and baseline value.
Changes in ART from SCT to CT at any point during the first 48 weeks of the trial for those randomised to
SCT were summarised by reason for changing strategy. Changes in ART regimen were summarised by arm.
Major HIV-1 resistance mutations39 at the point of VL failure or any time after VL failure were summarised
for any VL failures in the first 48 weeks, overall and by drug class. CDC stage B and C events, as well as
any deaths, were summarised by arm.
METHODS
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Measuring adherence was an important aspect of the analysis as we were attempting to see whether or
not randomised strategies were being adhered to. We measured adherence to the protocol in two ways:
first, through adherence questionnaires and, second, through a MEMSCap™ Medication Event Monitoring
System (MEMSCap Inc., Durham, NC, USA) substudy on a subset of 61 patients.
Acceptability questionnaires were summarised at baseline and week 48, and the comparison between
what young people found difficult before the study and what they found difficult during the study was
examined using McNemar’s test.
Safety
Grade 3 and 4 clinical and laboratory AEs were summarised by arm. The difference in rate of grade 3 and
4 AEs between arms per 100 person-years was calculated using Poisson regression (with a random effect
for person) and the number of young people with any grade 3 or 4 AE was compared between arms using
a Fisher’s exact test. The same analyses were performed for ART-related AEs, treatment-modifying AEs and
serious adverse event (SAEs).
Inflammatory biomarkers substudy
Rationale behind methods and markers selected
The blood volume that can be collected in children is limited, which was a major influence on the
techniques selected for use in this study. In view of the global recruitment of the PENTA 16 trial, the assay
selection was also influenced by its robustness to freezing at –80 °C for variable periods of time.
A panel of 19 biomarkers has been studied in several trials by the immunology laboratory at the UCL
Institute of Child Health. Together they cover markers of inflammation (interleukin 1 receptor antagonist,
C-reactive protein, tumour necrosis factor alpha, interleukin 10, interleukin 6, interleukin 8), cardiovascular
injury (monocyte chemoattractant protein 1, angiopoietin-1 and -2, E-selectin, P-selectin, intercellular
adhesion molecule 3, thrombomodulin, serum amyloid A, soluble intercellular adhesion molecule 1, soluble
vascular cell adhesion molecule, vascular endothelial growth factor) and disordered thrombogenesis
[d-dimer, tissue factor (TF)].
Methods
Blood was collected in ethylenediaminetetra-acetic acid (EDTA) and spun within 4 hours of collection at
1500 g (≥ 2500 rpm) for 15 minutes to separate cells from plasma. The supernatant was removed and
placed in aliquots with a minimum of 500 µl of plasma in each cryovial. Samples were frozen at –70 °C
immediately. Repeat freeze–thaw cycles were avoided.
All samples were transported to the Institute of Child Health during September 2014 and the assays were
run in batches between October and December 2014. All standards were run in duplicate. Initial work
within the laboratory showed that the coefficient of variance between duplicate samples was ≤ 10%.
Given the small volumes of blood available and the cost of the plates, 95% of samples were run singularly,
with 5% duplicated to ensure consistent intra- and inter-assay precision. The lower limit of detection,
determined by the mean plus 2 standard deviations of the output signal of 10 blank samples, was
calculated for each biomarker.
Meso Scale Discovery technique
A total of 17 biomarkers were analysed using Meso Scale Discovery® (MSD) assays (Gaithersburg, MD, USA).
MSD assays use an electrochemiluminescence detection method similar to a sandwich enzyme-linked
immunosorbent assay (ELISA) technique. High-binding carbon electrodes in the base of microplates have a
10 times greater binding capacity than polystyrene. Electrochemiluminescent (SULFO-TAG) labels are
conjugated to detection antibodies. Within the analyser, electricity applied to the plate electrodes causes
light emission by the SULFO-TAG labels. Light intensity is then measured to quantify analytes in the sample.
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Multiple excitation cycles of each label amplify the signal to enhance light levels and improve sensitivity
allowing ultrasensitive assays to be run [see www.mesoscale.com/technical_resources/our_technology/ecl/
(accessed 18 February 2015)].
Five MSD plates were used. Table 1 lists the plates with the biomarkers on each plate. Assays were
conducted according to standard manufacturer’s protocols. Samples were read using the QuickPlex SQ
analyser (MSD).
Tissue factor
Tissue factor levels were measured using a commercial quantitative sandwich ELISA kit (Quantikine® ELISA
Human Coagulation Factor III/Tissue Factor R&D Systems, Minneapolis, MN, USA). A total of 100 µl of
assay diluent was added to 96-well microplates precoated with a monoclonal antibody against human TF.
Subject plasma was diluted twofold in Calibrator diluent RD5-20 (R&D Systems). The 100-µl standards and
then 100-µl diluted subject plasma were added and incubated for 2 hours at room temperature on a
horizontal orbital microplate shaker set at 600 rpm. The plate was manually washed four times using wash
buffer and excess fluid was removed by tapping the plate on a paper towel before 200 µl of TF enzyme-
linked polyclonal antibody conjugate was added. After a further 2 hours’ incubation the wash cycle was
repeated and 200 µl of substrate solution [stabilised hydrogen peroxide/chromogen (tetramethylbenzidine)]
was added. The plate was then protected from light during a final 30-minute incubation, after which 50 µl
TABLE 1 List of biomarkers on each plate
Method Plate Biomarker Units Lower level of detection
MSD Vascular injury-1 TM ng/ml 0.064
ICAM-3 ng/ml 0.064
E-selectin ng/ml 0.064
P-selectin ng/ml 0.064
Vascular injury-2 SAA pg/ml 10.9
CRP pg/ml 1.33
VCAM-1 pg/ml 6.0
ICAM-1 pg/ml 1.03
Custom cytokine IL-6 pg/ml 0.192
IL-8 pg/ml 0.132
IL-10 pg/ml 0.0806
MCP-1 pg/ml 0.116
TNF-α pg/ml 0.0798
VEGF pg/ml 0.229
IL-1RA IL-1RA pg/ml 2.44
Angiopoeitin-1 and -2 Angiopoietin-1 pg/ml 24.4
Angiopoietin-2 pg/ml 2.44
ELISA TF TF pg/ml 0.69
D-dimer D-dimer ng/ml 0
CRP, C-reactive protein; ICAM-1, intercellular adhesion molecule 1; ICAM-3, intercellular adhesion molecule 3;
IL-1RA, interleukin 1 receptor antagonist; IL-6, interleukin 6; IL-8, interleukin-8; IL-10, interleukin 10; MCP-1, monocyte
chemoattractant protein-1; SAA, serum amyloid A; TNF-α, tumour necrosis factor alpha; VCAM-1, vascular cell adhesion
molecule 1; VEGF, vascular endothelial growth factor.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
of stop solution was added, and optical density was measured within 30 minutes using a microplate reader
(Thermo Scientific Multiskan® EX) set to 450 nm. A four-parameter logistic curve fit was calculated using
Ascent software 2.6 (Thermo Labsystems Oy, Basingstoke, UK) and the concentration read from the
standard curve and multiplied by the dilution factor of two.
D-dimer
The commercial TECHNOZYM® D-dimer ELISA assay (Technoclone, Vienna, Austria) was chosen following a
comparison of two ELISA methods with two automated methods used in the NHS coagulation laboratory
at Great Ormond Street Hospital. This provided consistent results and required smaller volumes of blood
than the automated methods.
Undiluted samples were used after pilot runs showed that most patients had levels of D-dimer below the
limit of detection when a twofold dilution was used. A total of 100 µl of calibrator and sample were added to
wells precoated with anti-D-dimer monoclonal antibody and were then incubated at 37 °C for 60 minutes.
Following manual plate washing three times using wash buffer (pH 7.3), 100 µl of conjugate (monoclonal Anti
D-dimer-POX) working solution was added before a further 60-minute incubation at 37 °C. Following
a second plate wash, 100 µl of substrate solution (chromogen tetramethylbenzidine) was added. After a
10-minute incubation at room temperature, 100 µl of stop solution (sulphuric acid) was added and the plate
read immediately using a microplate reader (Multiskan EX) set to 450 nm. A linear regression curve fit was
calculated using Ascent software 2.6 and the concentration read from the standard curve.
Statistical methods
Two linear regression models were fitted for each biomarker, at 48 and 96 weeks, adjusting for baseline
biomarker value and randomised arm. However, because of the non-normal distribution of each
biomarker, the natural logarithm was used to fit the models.
Immunology substudy
Rationale for an immunology substudy
A study comparing CD4-guided planned treatment interruptions of ART with CT in HIV-1-infected children
was performed between 2004 and 2006.40 The key immunological findings were that (1) there was a rapid
fall in CD4 cells that occurred early following treatment interruption; (2) there was a rapid increase in CD8
cells peaking at 8 weeks after the planned treatment interruption; and (3) there were changes in naive and
memory cell subsets within both the CD4 and the CD8 cell populations.41 This study informed our focus on
these cell populations to determine whether or not treatment interruption in the BREATHER trial would
have an impact on immune dynamics.
Methods
The CD4 and CD8 lymphocyte subsets were quantified locally on fresh samples collected. In some centres,
CD45RA and CD45RO subpopulations of CD4 and CD8 cells were also evaluated on fresh samples.
In centres able to separate and store cells, additional whole blood was collected in EDTA and peripheral
blood mononuclear cells isolated by density gradient centrifugation, divided into aliquots and frozen.
A range of established markers was used to quantify naive and memory cells. These varied between
laboratories but always included antibodies to detect CD45RA and CD45RO; in some laboratories, CD27
and CD31 were also included.
Statistical methods
Linear models of the CD45RA/CD45RO ratio, adjusting for baseline CD45RA/CD45RO ratio and
randomised arm, were fitted at 48 weeks. Similar models were fitted for CD45RA%/CD45RO%, CD8RA/
CD8RO and CD8RA%/CD8RO%. Because of non-normal distributions of these ratios, the natural
logarithm of each ratio was used to fit the models.
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Virology substudy
Statistical methods
We compared the proportion of individuals at week 48 with a VL of ≥ 20 copies/ml with the proportion
with a VL of ≥ 50 copies/ml from the main trial analysis. Additionally, we investigated the difference
between arms in the proportion of young people with a VL of ≥ 20 copies/ml at week 48 and tested the
difference using a Fisher’s exact test.
We examined how many individuals who failed during the first 48 weeks of the main trial had a screening
(or baseline if no screening sample available) VL of ≥ 20 copies/ml.
Finally, we compared the proportion of young people in each arm who had a VL of < 20 copies/ml at
screening (or baseline if no screening sample available) and a VL of ≥ 20 copies/ml at week 48 using a
Fisher’s exact test.
Laboratory methods
Ultrasensitive quantitative HIV-1 ribonucleic acid assay
The quantitative HIV-1 RNA assay used the Qiagen QIASymphony® SP (Manchester, UK) automated nucleic
acid extraction procedure for extraction of HIV-1 RNA from 1ml of plasma sample. An ABI Prism 7500
(Foster City, CA, USA) real-time PCR instrument with Invitrogen (Carlsbad, CA, USA) reverse transcription
polymerase chain reaction (RT-PCR) reagents was used for amplification and detection of HIV-1 RNA. The
quantification is based on an in-house standard curve calibrated against the World Health Organization
hepatitis C virus international standard in IU/ml. The assay uses brome mosaic virus RNA as an internal
control, which is introduced at the extraction stage. The multiplex real-time RT-PCR detects both HIV and
brome mosaic virus with differently labelled TaqMan® probes.
Quantitative total HIV-1 deoxyribonucleic acid assay
The quantitative HIV-1 deoxyribonucleic acid (DNA) assay used the Qiagen DNA mini blood kit for
extraction of DNA. An ABI Prism 7500 real-time PCR instrument with Invitrogen RT-PCR reagents was used
for amplification and detection of HIV-1 DNA. The quantification is based on a standard curve using 8E5
cells and carrier RNA (Qiagen lot:139285838). Absolute maximum amount of input DNA in a PCR is
600 ng per reaction. The lower limit of dilution is 10 HIV copies/million cells (patients on HAART and
undetectable HIV RNA in plasma usually have a total HIV DNA level of around 100 HIV copies/ml). The
assay uses pyruvate dehydrogenase DNA as an internal control. The multiplex real-time RT-PCR detects
both HIV and pyruvate dehydrogenase with differently labelled TaqMan probes. Results are reported as
copies of HIV per million cells.
Qualitative substudy
Sample
All young people recruited into the BREATHER trial in the UK, Ireland, Uganda and the USA aged
10–24 years were eligible to participate in the qualitative substudy, subject to the appropriate consents
and self-awareness of HIV infection (for at least 6 months). Although the trial included children from the
age of 8 years, the qualitative study involved trial participants who were aged ≥ 10 years only and aware
of their HIV status. Although we appreciate that age can be an inadequate proxy for HIV awareness, this
decision was guided by ethical concerns about the extent to which children under the age of 10 years
could have achieved the considerable understanding about HIV infection necessary for the in-depth
discussions in the qualitative interviews.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
In our design we had envisaged that we would adopt a purposive sampling strategy giving primary
emphasis to ‘responsibility for medication’ (sole, shared, carer), with secondary dimensions including age
(spread as per trial), gender, ethnicity, membership of HIV youth support groups, current domestic
situation (living with parent(s), extended kin) and school attendance. However, given the lower than
expected levels of recruitment into the trial in the UK and Ireland, we involved anybody who was eligible
and willing to participate. In the US site, given the nature and timing of the fieldwork we adopted the
same strategy, which meant that we involved all participants who had thus far been recruited into the trial.
In Uganda, excluding those who were in the pilot, we initially adopted a similar recruitment strategy as in
the other sites and then purposively selected the last 10 in our sample to ensure that we were reflecting a
broad range of sample characteristics. The qualitative sample in each site reflects the diversity of the
trial population.
Overall, 102 interviews were conducted with 43 young people (Table 2). In total, 26 young people were
recruited in Uganda from one clinic (Joint Clinical Research Centre, Kampala), seven were recruited in the
UK from three clinics (NHS hospitals in London, Nottingham and Dublin) and 10 were recruited in the USA
from one clinic (St. Jude’s Children’s Research Hospital, Memphis, TN).
Recruitment response and retention through the repeated phases of the qualitative study was high (around
40%). We had very high rates of participation in the Uganda (26 out of a possible 66 trial participants) and
US sites (10/14). Recruitment was most challenging in the UK and Ireland (7/23). Overall, we included 40%
of the trial participants who were aged ≥ 10 years. However, the actual proportion of eligible participants
recruited is likely to have been higher than this, given that this figure does not account for the participants
who would not have been eligible despite being within the age range because of a lack of awareness of
their HIV status.
The majority of refusals occurred in the UK sites, with the reasons for refusal varying. Very few participants
had taken part in qualitative research before and some of the young people were unwilling to talk to the
researchers and were uncomfortable with the idea of the qualitative interviews. Others instead mentioned
not wanting to take on any additional clinic attendance and time commitments. This may reflect the
amount of overall research being conducted with the relatively small UK cohort, but could also be
indicative of the desire that young people have to minimise the time spent in the clinic and focus on other
aspects of their lives aside from HIV.
TABLE 2 Qualitative sample overview
Country Total (n) Male (n) Female (n) On SCT (n) On CT (n)
Switched or
left trial (n)
Age
(years),
mean
Age
(years),
range
Uganda 26 12 14 14 10 2 (to CT) 18 11–22
UK (and Ireland) 7 5 2 4 3 – 15 12–17
USA 10 9 1 4 5 1 (from trial) 21 18–22
Total 43 26 17 22 18 3 17 11–22
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Types of data collected
1. One-to-one interviews with young people living with HIV. In Uganda, participants were interviewed
three times over the course of the study (in the early stages of the trial; towards the end of the trial;
and during the follow-up period) to explore their experience of adherence and the process of the trial.
In the UK and US sites, only the first two interviews were conducted. Interviews lasted approximately
1–2 hours and were audio-recorded, subject to consent. Baseline interviews captured life with HIV on
HIV treatment as described by young people and included, but did not focus specifically on, young
people’s perceptions of the trial or of SCT. The second interview reconstructed the life and treatment
trajectory of participants since the start of the trial, focusing on adherence during this specific time
period as well as reflections on intervention and trial acceptability. The third interview in Uganda was
conducted as participants moved into the follow-up stage of the study. In these interviews we explored
any changes in their treatment experience and their attitudes towards continuing in the intervention or
control arm. The third interviews are being conducted in the UK only at trial end to explore participants’
reactions to the outcome of the trial. Reactions to the trial results will be explored informally in Uganda
through meeting observations and discussions. It is worth noting that the focus of the third interview
has changed from the preliminary study design in response to the changes made in the trial. The third
interview was initially planned to explore how participants would adapt had they been required at the
end of the trial to switch back from the SCT arm to CT. However, this has not occurred and participants
have been retained in the same arm through the follow-up phase. The focus of the qualitative enquiry
has shifted to reflect these changes and instead will consider how participants respond to continuing in
the same arm and their attitudes towards SCT once the main trial findings have been disseminated.
2. Audio diaries of young people living with HIV. We piloted the use of audio diaries in the UK and
Uganda sites. This is an innovative method that we have used before and we consider such diaries to
be a valuable method in capturing personal reflections.42 We wanted to explore whether or not this
method would enable participants to generate data at the time and space of their choosing and if this
would provide particular insights into the immediacy and variability of treatment and adherence
experiences. We therefore offered this method to assess its feasibility and value for research with young
people. All participants were offered the chance to keep an audio diary in the Uganda and UK sites.
Ethical approval was not given for the audio diaries to be used in the US site. In Uganda, 12
participants agreed to contribute a personal audio diary and in the UK three participants took up the
opportunity. We found that there were significant challenges to using audio diaries with this age group
in these sites for such a sensitive topic. Despite participants’ initial enthusiasm to use the diaries we
found that their lack of privacy within their own home, exacerbated for many (especially those in
Uganda) by a lack of physical space, meant that it was difficult for them to first record their diaries with
ease and second be confident of securely storing them before returning them to the research team.
These conditions undermined the value of the method, as the premise that participants may be able to
speak more freely about immediate events with greater convenience could not be realised. Those who
did record something mainly recorded public interactions or songs, which were not related to our topic
of enquiry. We may conclude from this pilot that use of audio diaries is unlikely to be a feasible method
given the restraints of a lack of privacy.
METHODS
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Ongoing research: planned data collection
1. Phase 3 interviews with young people in the trial in the UK post publication of trial findings. In the UK
we are conducting a third and final interview which explores attitudes towards SCT in light of the trial
findings. Our research focus has been adjusted to reflect the trial plans. It remains rare for participants
to be asked about their response to trial findings and we anticipate that this may provide a valuable
model for informing the design of any further development of this intervention and future roll-out.
2. Interviews with carers of young people in the trial (Uganda). In Uganda, all participants have been
asked to consent to their carers being contacted to take part in an interview. Using thematic sampling
criteria, informed by our initial analysis, we are inviting 15 carers to participate in an interview to
explore their response to the trial findings. The interview also explores their decision-making process in
consenting for their child to participate in the trial, their reflections on how their expectations aligned
with their experience of the trial and their perceptions of the barriers to and facilitators of adolescents’
adherence, including the impact of the trial.
3. Focus groups with young people living with HIV not involved in the trial. In Uganda data are being
collected in focus groups with up to 25 HIV-positive young people aged 10–24 years who participated
in the trial. This is subject to the appropriate consents and self-awareness of HIV infection (for at least
6 months). These focus groups explore young people’s understandings of the results of the trial,
their experience in the trial and its influence as their adherence patterns, through peer discussion.
We endeavour to ensure that these groups reflect the diversity of the trial population. Data transcription
and, where appropriate, translation from these additional sets of data collection are ongoing.
Data analysis is being carried out iteratively to inform subsequent data collection and refine questions.
Consent procedures and ethics
Consent was sought from all trial participants aged 10–24 years who had been aware of their status for at
least 6 months. Participants were approached in different ways depending on the local procedures of each
of the research sites. In the UK, research nurses contacted and consented participants, although the
researcher had a number of conversations over the telephone with participants to answer their questions
and discuss the topic before they decided whether or not to take part. In the USA, trial staff carried out
both the contacting and the consent procedures. In Uganda, the researcher met the carers in the clinic and
explained the qualitative study to them and then asked for their consent for the children to participate.
This was followed by an ‘assent’ procedure with the children themselves. In all sites, final arrangements for
the interviews were organised with the researcher.
In line with Good Clinical Practice principles [see www.ich.org/products/guidelines/efficacy/efficacy-single/
article/good-clinical-practice.html (accessed 6 April 2016)], informed consent was treated as a process. This
involved reminding participants at each stage of the study what the qualitative study was about, answering
any related questions that they may have had, providing information as appropriate and reiterating that
participants could withdraw at any time during the process of data collection. We did not need to break
confidentiality on any safeguarding issues, although we had plans in place should this have been necessary.
The data that were collected were transcribed verbatim and, when appropriate, were translated into
English by the research assistant. Personal identifying details were removed. We have been given an
exemption from the mandatory request by the Economic and Social Research Council to archive the
Ugandan data given the sensitivity and contextually dense nature of the data collected.
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Modes of analysis/interpretation
The study adopted a grounded analytic approach to thematic analysis, using systematic case comparison
and negative case analysis throughout.43 We orientated analyses by themes emerging within/across
individual accounts, exploring the acceptability of the trial; the potential value of SCT; and barriers to
adherence as it converges with changing priorities during adolescence, as well as to the advancement of
social science research and theory on HIV treatment adherence.
All interviews and audio diaries were transcribed verbatim by the data assistants. As discussed above,
the limitations in the audio diary data meant that these data have not been integrated into our analysis.
In line with our iterative analysis approach, we analysed data as we collected it to inform the direction of
subsequent interviews, further coding and case selection. In addition to giving attention to ‘negative cases’
through case comparisons in our analysis, we sought respondent validation on emerging conclusions and
maximised internal reliability and reflection through comparing coding between multiple researchers.
Coding was undertaken in two linked phases. Our first-level coding drew on a combination of a priori
themes reflected in the study topic guide and inductive or in vivo codes.44 Our second-level coding sought
to break down first-level coded data into smaller units, which also involved moving from codes that
operate at the level of participant description and meaning to concept-driven categories. This process is
similar to moving from ‘open’ to ‘axial’ to ‘selective’ coding in grounded theory.43 We have maintained an
audit trail of the analytical process, including analytical memos and how case comparisons and attention to
emerging negative cases have informed ongoing analyses. We have conducted analysis by site and across
the study to identify if gender, age and country are significant in how we can disaggregate our findings.
METHODS
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Chapter 3 Results from the main trial
Baseline characteristics
In total, 199 young people were randomised from 11 countries between 1 April 2011 and 28 June 2013
(Table 3). A Consolidated Standards of Reporting Trials diagram for the trial can be found in Figure 1.
Baseline demographic data were well matched between arms, with 105 (53%) male participants, a median
(IQR) age of 14.1 (11.9–17.6) years and a median (IQR) weight of 45.2 (33.8–56.0) kg. In total, 35% of all
young people randomised were recruited from an African site; 180 (90%) young people were vertically
infected; and 41 (21%) were white, 112 (56%) were black and 37 (19%) were Asian (Table 4).
TABLE 3 Enrolment by country
Country (number of sites) Dates of first and last randomisation
Number randomised
SCT CT Total
Argentina (2) 13 December 2012 28 May 2013 5 6 11
Belgium (1) 29 April 2013 6 May 2013 1 1 2
Denmark (1) 25 September 2012 4 December 2012 2 1 3
Germany (1) 26 June 2013 26 June 2013 1 2 3
Ireland (1) 11 April 2012 9 October 2012 3 0 3
Spain (5) 5 September 2011 4 July 2012 6 5 11
Thailand (3) 5 July 2011 27 June 2013 15 21 36
Uganda (1) 23 May 2011 28 June 2013 35 35 70
UK (7) 1 April 2011 10 June 2013 14 12 26
Ukraine (1) 21 March 2013 17 June 2013 10 10 20
USA (1) 22 August 2012 24 April 2013 7 7 14
Total (24) 1 April 2011 28 June 2013 99 100 199
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(n = 99)
• Received allocated intervention, n = 99
• Did not receive allocated intervention, n = 0
Allocated to CT
(n = 100)
• Received allocated intervention, n = 100
• Did not receive allocated intervention, n = 0
Analysed
(n = 99)
• Excluded from analysis, n = 0
Analysed
(n = 100)
• Excluded from analysis, n = 0
Lost to follow-up
(n = 0)
• Due to reaching primary end point, n = 6
• Poor adherence, n = 1
• AE, n = 1
Lost to follow-up
(n = 1)
Discontinued intervention
(n = 8)
Discontinued intervention
(n = 0)
• Young person moved to a different 
    country, n = 1
FIGURE 1 Consolidated Standards of Reporting Trials diagram.
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TABLE 4 Baseline characteristics: demographics
Characteristic SCT CT Total
Young people randomised, n 99 100 199
Sex, n (%)
Male 57 (58) 48 (48) 105 (53)
Female 42 (42) 52 (52) 94 (47)
Age (years)
Mean (SD) 14.5 (3.9) 14.7 (3.9) 14.6 (3.9)
Median (IQR) 13.7 (11.7–17.7) 14.4 (12.0–17.5) 14.1 (11.9–17.6)
Range 8.0–24.2 8.3–24.0 8.0–24.2
Age range, n (%)
≥ 8 to < 13 years 38 (38) 39 (39) 77 (39)
≥ 13 to < 18 years 39 (39) 41 (41) 80 (40)
≥ 18 to < 24 years 22 (22) 20 (20) 42 (21)
Weight (kg)
Mean (SD) 46.9 (18.2) 45.6 (14.8) 46.2 (16.6)
Median (IQR) 45.5 (33.1–56.2) 45.1 (33.9–55.7) 45.2 (33.8–56.0)
Range 18.0–114.3 20.0–90.1 18.0–114.3
Route of infection, n (%)
Vertical 90 (91) 90 (90) 180 (90)
Sexual contact 7 (7) 7 (7) 14 (7)
Blood product 1 (1) 2 (2) 3 (2)
Unknown 1 (1) 1 (1) 2 (1)
Ethnic origin, n (%)
White 24 (24) 17 (17) 41 (21)
Black: African or other 58 (59) 54 (54) 112 (56)
Mixed black/white 0 (0) 4 (4) 4 (2)
Asian 15 (15) 22 (22) 37 (19)
Other 2 (2) 3 (3) 5 (3)
Recruited from African site, n (%) 35 (35) 35 (35) 70 (35)
SD, standard deviation.
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There was a minor imbalance at baseline in CDC events, with 13% of young people in the SCT arm
having had a CDC stage C event compared with 21% in the CT arm. The median (IQR) CD4% at
randomisation was 34.0% (29.5–38.5%) and the median (IQR) absolute CD4 count was 735.0 cells/mm3
(575.5–967.5 cells/mm3) (Table 5).
Twenty-nine (14.6%) young people had had previous exposure to PIs at randomisation, but none had
switched from PIs because of virological failure, and at trial entry all young people were on regimens
containing NRTIs and EFV only.
In baseline acceptability questionnaires completed by young people randomised to SCT, 70 out of 80
(87.5%) young people who answered the questionnaires said that they thought that taking weekends off
treatment would make things either much easier or a little easier compared with taking ART continuously.
TABLE 5 Baseline characteristics: HIV-related parameters
Characteristic SCT CT Total
Young people randomised, n 99 100 199
CDC stage, n (%)
N 16 (16) 10 (10) 26 (13)
A 25 (25) 25 (25) 50 (25)
B 45 (45) 43 (43) 88 (44)
C 13 (13) 21 (21) 34 (17)
Missing 0 1 (1) 1 (1)
CD4%
Mean (SD) 34.7 (6.8) 34.1 (6.4) 34.4 (6.6)
Median (IQR) 34.5 (29.3–39.0) 34.0 (29.5–38.1) 34.0 (29.5–38.5)
CD4%, n (%)
< 30% 26 (26) 27 (27) 53 (27)
≥ 30% to < 40% 52 (53) 55 (55) 107 (54)
≥ 40% 21 (21) 18 (18) 39 (20)
Missing 0 0 0
CD4 (cells/mm)
Mean (SD) 787.3 (297.6) 798.7 (308.3) 793.0 (302.3)
Median (IQR) 722.5 (581.0–965.0) 747.3 (575.3–972.8) 735.0 (575.5–967.5)
CD4 (cells/mm), n (%)
≥ 350 to < 1000 79 (80) 79 (79) 158 (79)
≥ 1000 to < 1500 17 (17) 17 (17) 34 (17)
≥ 1500 3 (3) 4 (4) 7 (4)
Missing 0 0 0
RESULTS FROM THE MAIN TRIAL
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Follow-up
At the end of the trial, the median (IQR) follow-up time was 85.7 (62.0–118.3) weeks. Two young people,
both from the CT arm, were lost to follow-up by the end of the trial, one because of leaving the country
after the week 24 visit and the other because of transferring to an adult clinic and withdrawing consent
after the week 48 visit. Attendance to clinic visits was good, with > 90% of young people still in follow-up
attending each visit (Table 6).
TABLE 6 Follow-up to the end of the trial
Follow-up SCT CT Total
Participants randomised, n 99 100 199
Seen at the following weeks, n (%) [%]a
1 15 (100)b [100]b 17 (100)b [100]b 32 (100)b [100]b
2 15 (100)b [100]b 17 (100)b [100]b 32 (100)b [100]b
3 15 (100)b [100]b 17 (100)b [100]b 32 (100)b [100]b
4 98 (99) [99] 98 (98) [98] 196 (98) [98]
8 15 (100)b [100]b 15 (88)b [88]b 30 (94)b [94]b
12 98 (99) [99] 99 (99) [99] 197 (99) [99]
24 99 (100) [100] 100 (100) [100] 199 (100) [100]
36 98 (99) [99] 97 (97) [98] 195 (98) [98]
48 95 (96) [96] 94 (94) [96] 189 (95) [96]
60 93 (94) [97] 89 (89) [98] 182 (91) [97]
72 68 (69) [96] 70 (70) [99] 138 (69) [97]
84 66 (67) [100] 56 (56) [97] 122 (61) [98]
96 43 (43) [91] 44 (44) [96] 87 (44) [94]
108 39 (39) [100] 38 (38) [97] 77 (39) [99]
120 26 (26) [96] 26 (26) [100] 52 (26) [98]
132 12 (12) [86] 17 (17) [106] 29 (15) [97]
144 13 (13) [100] 13 (13) [93] 26 (13) [96]
156 8 (8) [100] 7 (7) [100] 15 (8) [100]
168 1 (1) [100] 0 (0) [0] 1 (1) [100]
Weeks from randomisation to last visit
Median (IQR) 86.3 (62.4–118.9) 84.9 (60.9–117.1) 85.7 (62.0–118.3)
Range 49.0–169.0 25.0–158.0 25.0–169.0
Mean 94.8 92.5 93.7
Lost to follow-up, n (%) 1 (1)c 2c (2) 3c (2)
a Percentage of those still in the trial.
b Percentage of young people in the pilot study (who were seen at weeks 1, 2, 3 and 8 when young people in the main
trial were not).
c One young person was lost to follow-up (left the country) at week 24 and one young person transferred to adult care
and withdrew consent after week 48. GB071003B transferred at W108 to adult care at a hospital where we were
unable to obtain any further follow-up data.
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Primary end point
Thirteen young people reached the primary end point by the end of the 48-week assessment, six from the
SCT arm and seven from the CT arm. In the primary analysis, the estimated probability (90% CI) of
reaching the primary end point was 6.1% (2.1% to 10.2%) for individuals in the SCT arm and 7.3%
(2.9% to 11.7%) for those in the CT arm. The estimated difference between arms (SCT –CT) was 1.2% in
favour of SCT (90% CI –7.3% to 4.9%) and so the upper bound of the 90% CI was less than the
non-inferiority margin of 12% (Figure 2).
Week 48 assessment
Treatment arm Number of events Person-years at risk Estimated probability of failinga 90% CI
SCT 6 99.53 0.061 0.021 to 0.102
CT 7 98.75 0.073 0.029 to 0.117
Difference (SCT –CT) –0.012 –0.073 to 0.049
a Adjusted for age range (8–12, 13–17, 18–24 years), African site and African site × age range interaction.
Therefore, at the end of the 48-week assessment, the results are consistent with the non-inferiority of SCT
compared with CT.
When not adjusting for stratification factors, the estimated probability (90% CI) of reaching the primary
end point was 6.1% (3.2% to 11.7%) in the SCT arm and 7.3% (4.0% to 13.1%) in the CT arm. The
estimated difference between arms (SCT –CT) was 1.1% in favour of SCT (90% CI –6.8% to 4.6%) and
so the upper bound of the CI was less than the non-inferiority margin of 12% (Figure 3). Therefore,
non-inferiority was demonstrated in this analysis as well as in the primary analysis.
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FIGURE 2 Adjusted Kaplan–Meier estimates of time to first detected HIV-1 RNA ≥ 50 copies/ml (confirmed) up to
the week 48 assessment.
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Week 48 assessment
Treatment arm Number of events Person-years at risk Estimated probability of failing 90% CI
SCT 6 99.53 0.061 0.032 to 0.117
CT 7 98.75 0.073 0.040 to 0.131
Difference (SCT –CT) –0.011 –0.068 to 0.046
p-valuea= 0.754
a Log-rank test.
The crude proportion (90% CI) of young people experiencing virological failure was 0.061 (0.027 to 0.116)
in the SCT arm and 0.070 (0.033 to 0.127) in the CT arm. Therefore, the estimated difference in crude
proportion (90% CI) between arms (SCT –CT) was –0.009 (–0.067 to 0.048) (Table 7).
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FIGURE 3 Kaplan–Meier graph of time to first detected HIV-1 RNA ≥ 50 copies/ml (confirmed) up to the
48-week assessment.
TABLE 7 Difference in the proportion of young people with HIV-1 RNA ≥ 50 copies/ml (confirmed) at any time from
randomisation to the week 48 assessment
Treatment arm Number of events Estimated proportion 90% CI p-valuea
SCT 6 0.061 0.027 to 0.116
CT 7 0.070 0.033 to 0.127
Difference (SCT –CT) –0.009 –0.067 to 0.048 1.000
a Fisher’s exact test.
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Secondary end points
Virology
The primary analysis was repeated but with the end point as a confirmed HIV-1 RNA VL of ≥ 400 copies/ml.
The estimated difference between arms (SCT –CT) in the proportion of virological failure was 2.1% in
favour of SCT (90% CI –6.2% to 1.9%), which is consistent with the non-inferiority of SCT compared with
CT (Figure 4).
Week 48 assessment
Treatment arm Number of events
Person-years
at risk
Estimated probability
of failinga 90% CI
SCT 2 101.35 0.021 –0.000 to 0.044
CT 4 99.72 0.042 0.010 to 0.075
Difference (SCT –CT) –0.021 –0.062 to 0.019
Bootstrap p= 0.381
a Adjusted for age range (8–12, 13–17 and 18–24 years), African site and African site × age range interaction.
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FIGURE 4 Adjusted Kaplan–Meier estimates of time to first detected HIV-1 RNA ≥ 400 copies/ml (confirmed) up to
the week 48 assessment.
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The results when analysing without adjusting for stratification factors remained qualitatively unchanged
(data not shown).
The crude proportion (90% CI) of young people experiencing virological failure (≥ 400 copies/ml) was
0.020 (0.004 to 0.062) in the SCT arm and 0.040 (0.014 to 0.089) in the CT arm. Therefore, the estimated
difference in crude proportion (90% CI) experiencing virological failure between arms (SCT –CT) was
–0.020 (–0.060 to 0.020) (Table 8).
Immunology
There were no significant differences between arms at any clinic visit after randomisation in CD4%, CD4
count, CD4 z-score, CD8%, CD8 count, CD3% or CD3 count (data not shown).
Biochemistry
There were no significant differences between arms at any clinic visit after randomisation in creatinine,
bilirubin, alkaline phosphatase, AST, ALT, glucose, triglycerides, very-low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol or total cholesterol (data not shown). A significantly higher level of LDL
cholesterol was observed in the SCT arm at week 24, but this difference appears to be transient, as there
was no significant difference between arms at week 36 or week 48 (Table 9 and Figure 5).
TABLE 8 Difference in proportion of young people with HIV-1 RNA ≥ 400 copies/ml (confirmed) at any time from
randomisation to the week 48 assessment
Treatment arm Number of events Estimated proportion 90% CI p-valuea
SCT 2 0.020 0.004 to 0.062
CT 4 0.040 0.014 to 0.089
Difference (SCT –CT) –0.020 –0.060 to 0.020 0.683
a Fisher’s exact test.
TABLE 9 Mean change in LDL cholesterol (mg/dl) from randomisation to week 48
Weeks since
randomisation
SCT CT
p-value
(unadj)
Adjustedb difference
n
Mean
changea SE n
Mean
changea SE Meanb SE 95% CI
p-value
(adjb)
12 20 2.9 8.0 18 8.2 8.2 0.65 –3.7 11.4 –26.9 to 19.4
0.75
24 81 4.3 1.8 83 –3.8 1.8 0.00 8.4 2.5 3.4 to 13.4 0.00
36 16 –0.9 4.0 16 –3.0 3.9 0.70 5.8 5.0 –4.6 to 16.1 0.26
48 89 1.3 1.7 92 –0.3 1.6 0.49 1.5 2.3 –3.1 to 6.1 0.52
adj, adjusted; SE, standard error; unadj, unadjusted.
a Change in LDL cholesterol calculated using linear regression of LDL cholesterol after randomisation, adjusting for
baseline LDL cholesterol, presenting mean change from a baseline LDL cholesterol of 92.04mg/dl.
b Linear regression adjusted for the stratification factors (age range, African site and African site × age range interaction) in
addition to baseline LDL cholesterol.
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Haematology
There were no significant differences between arms at any clinic visit after randomisation in haemoglobin
level, white blood cell count, lymphocyte count or neutrophil count (data not shown). However, a
significantly lower platelet count was observed in the SCT arm at each week after randomisation (Table 10
and Figure 6). Additionally, a significantly lower MCV was observed in the SCT arm each week after
randomisation (Table 11 and Figure 7).
Status of young people randomised to short-cycle therapy
Of the 99 young people randomised to SCT, 91 (91.9%) were still taking weekends off treatment by the
end of the week 48 assessment and eight (8.1%) had changed strategy to continuous ART. Of the eight
who changed strategy, six did so because they reached the primary end point and therefore they changed
as per protocol. One young person changed strategy because of an AE (gynaecomastia), which led him to
come off EFV and therefore restart CT as per protocol, and one young person had adherence issues that
were noticed by the clinician and she was instructed to return back to CT (Table 12).
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FIGURE 5 Mean change in LDL cholesterol (mg/dl) from randomisation to week 48.
TABLE 10 Mean change in platelet count (per l) from randomisation to week 48
Weeks since
randomisation
SCT CT
p-value
(unadj)
Adjustedb difference
n
Mean
changea SE n
Mean
changea SE Meanb SE 95% CI
p-value
(adjb)
12 95 –9.8 6.0 99 12.6 5.9 0.01 –21.7 8.2 –37.8 to –5.6 0.01
24 97 –13.2 5.2 99 4.3 5.1 0.02 –17.2 7.3 –31.6 to –2.9 0.02
36 98 –16.2 5.4 96 –1.0 5.5 0.05 –15.2 7.7 –30.4 to 0.1 0.05
48 95 –13.4 6.5 94 7.4 6.6 0.03 –20.9 9.2 –39.1 to –2.6 0.03
adj, adjusted; SE, standard error; unadj, unadjusted.
a Change in platelet count calculated using linear regression of platelet count after randomisation, adjusting for baseline
platelet count, presenting mean change from a baseline platelet count of 300.68/l.
b Linear regression adjusted for the stratification factors (age range, African site and African site × age range interaction) in
addition to baseline platelet count.
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TABLE 11 Mean change in MCV (fl) from randomisation to week 48
Weeks since
randomisation
SCT CT
p-value
(unadj)
Adjustedb difference
n
Mean
changea SE n
Mean
changea SE Meanb SE 95% CI
p-value
(adjb)
12 92 –3.5 0.6 98 –1.0 0.6 0.00 –2.5 0.9 –4.2 to –0.8 0.00
24 95 –3.6 0.4 97 –0.9 0.4 0.00 –2.7 0.6 –4.0 to –1.5 0.00
36 94 –3.3 0.5 94 –1.3 0.5 0.00 –2.0 0.7 –3.3 to –0.7 0.00
48 94 –3.6 0.5 93 –1.6 0.5 0.01 –2.1 0.7 –3.5 to –0.6 0.00
adj, adjusted; SE, standard error; unadj, unadjusted.
a Change in MCV calculated using linear regression of MCV after randomisation, adjusting for baseline MCV, presenting
mean change from a baseline MCV of 93.48 fl.
b Linear regression adjusted for the stratification factors (age range, African site and African site × age range interaction) in
addition to baseline MCV.
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FIGURE 6 Mean change in platelet count (per l) from randomisation to week 48.
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FIGURE 7 Mean change in MCV (fl) from randomisation to week 48.
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Antiretroviral therapy changes
Twelve young people were on a different ART regimen at week 48 from the regimen that they were
randomised to, with a greater number of young people changing regimen in the CT arm (SCT, n= 3; CT,
n= 9; Fisher’s exact test, p= 0.13). All changes in ART during the first 48 weeks are presented in Table 13
(including two additional young people who stopped and restarted ART during follow-up but who were
back on their baseline regimen at week 48).
Resistance
Resistance tests were performed on all 13 young people who experienced virological failure up to the
48-week assessment. Four of these tests (SCT, n= 3; CT, n= 1) failed to amplify because of a low VL and
so resistance results were obtained for nine young people (SCT, n= 3; CT, n= 6). Seven (77.8%) young
people (SCT, n= 2; CT, n= 5) had major resistance mutations of any kind. Seven young people (SCT,
n= 2; CT, n= 5) had major NNRTI mutations (SCT arm: L100I+ Y188C+ K103N and K103N; CT arm:
E138A+ V106M, K103N+ V106M, M230L, V106M+ K103N and G190S) and two young people (SCT,
n= 1; CT, n= 1) also had the M184V mutation (Tables 14 and 15).
Centers for Disease Control clinical events and deaths
There were no new CDC C events or deaths during the first 48 weeks of the trial.
There were two new CDC stage B events, one in the SCT arm (grade 2 bronchopneumonia 10 weeks after
randomisation) and one in the CT arm (grade 1 bronchitis 0.3 weeks after randomisation).
Adherence
Analysis of questions on compliance to SCT strategy at follow-up visits showed good compliance, with
95% of weekend breaks being taken (99% excluding time after return to CT). Self-reported adherence
was similar in both arms, with 7% (29/414) reports in the SCT arm versus 10% (40/409) reports in the CT
arm of missing ART in the last week (excluding weekend breaks in SCT) (p= 0.42).
TABLE 12 Young people randomised to SCT but on continuous treatment by the end of the week 48 assessment
Reason for changing
strategy to CT Other reason details
Week changed
to CT
Number of weekends
off therapy before
changing to CT
Confirmed VL of ≥ 50 copies/ml 37.9 37
Confirmed VL of ≥ 50 copies/ml 29.1 29
Confirmed VL of ≥ 50 copies/ml 9.0 9
Confirmed VL of ≥ 50 copies/ml 49.6 49
Confirmed VL of ≥ 50 copies/ml 24.4 24
Confirmed VL of ≥ 50 copies/ml 50.6 50
Other reason Patient admitted that she had not
been taking her ART for 9–10 months
and she was instructed to return to CT
at this point
26.4 26
Other reason Patient returned to CT because of an
AEa resulting in EFV being stopped
35.0 32
a AE was grade 3 gynaecomastia.
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TABLE 13 Changes to ART regimena after randomisation to the week 48 assessment
Child Arm Week Regimen before Regimen after Reported reason for change
1 SCT 28.4 3TC ABC EFV 3TC ABC DRV Return/start
1 SCT 52.1 3TC ABC DRV – Compliance
2 SCT 35.1 FTC TDF EFV FTC TDF ATA Switch for toxicityb
3 SCT 35.1 ZDV 3TC EFV 3TC TDF EFV Simplification
1 CT 3.4 FTC TDF EFV DRV Stop for toxicityc
1 CT 16.7 DRV FTC TDF EFV Other
1 CT 20.0 FTC TDF EFV DRV Grade 1/2 AEd
2 CT 4.0 ZDV 3TC EFV 3TC TDF EFV Simplification
3 CT 4.0 ZDV 3TC EFV FTC TDF EFV Switch for toxicitye
4 CT 4.4 ZDV 3TC EFV – Temporary break
4 CT 5.6 – ZDV 3TC EFV Return/start
4 CT 35.7 ZDV 3TC EFV 3TC TDF EFV Switch for toxicitye
5 CT 4.0 ZDV 3TC EFV FTC TDF EFV Simplification
6f CT 26.9 FTC TDF EFV – Carer request
6 CT 29.3 – FTC TDF EFV Carer request
6 CT 45.3 FTC TDF EFV – Compliance
6 CT 46.3 – FTC TDF EFV Return/start
7f CT 27.0 3TC ABC EFV – Compliance
7 CT 33.0 – 3TC ABC EFV Return/start
8 CT 30.0 3TC ABC EFV 3TC ABC DRV Simplification
9 CT 48.6 ZDV 3TC EFV 3TC ABC EFV Switch for toxicitye
10 CT 50.3 ZDV 3TC EFV 3TC TDF LPV VL failure
11 CT 52.7 FTC TDF EFV – Compliance
ABC, abacavir; ATA, atazanvir; DRV, darunavir.
a Changes for ≥ 7 days.
b Young person switched from FTC TDF EFV to FTC TDF ATA because of an AE (gynaecomastia).
c Aminotransferases increased before randomisation.
d Aminotransferases increased (grade 2).
e Young person came off ZDV because of lipodystrophy, which occurred before randomisation.
f Young person made changes but was back on the baseline ART regimen at the 48-week assessment.
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TABLE 14 Number of major mutationsa in young people who experienced virological failure during the first
48 weeks of follow-up
SCT CT Total
Number of children with HIV-1 RNA > 50 copies/ml 6 7 13
Number of available sequences 3b 6b 9b
Number (%) of children with resistance mutations
Any class 2 (66.7) 5 (83.3) 7 (77.8)
NNRTI only 1 (33.3) 4 (66.7) 5 (55.6)
NRTI and NNRTI 1 (33.3) 1 (16.7) 2 (22.2)
Number of mutations per child, median (range)
All classes 2 (0–3) 2 (0–2) 2 (0–3)
PI 0 (0–0) 0 (0–0) 0 (0–0)
NRTI 0 (0–1) 0 (0–1) 0 (0–1)
NNRTI 1 (0–3) 1.5 (0–2) 1 (0–3)
a Major mutations are classified according to International Antiviral Society guidelines.39
b Four samples (n= 3 SCT: VL= 56 copies/ml, 126 copies/ml and 62 copies/ml; n= 1 CT: VL= 231 copies/ml) from young
people who experienced virological failure in the first 48 weeks failed to amplify.
TABLE 15 Major resistance mutations in individuals who experienced virological failure and their ART exposure
Arm Mutation class Mutations ART exposure
Week of virological failure
(resistance test)
SCT NNRTI only L100I K103N Y188C 3TC d4T EFV ZDV 48 (48)
SCT NRTI and NNRTI K103N M184V 3TC d4T EFV ZDV 50 (50)
CT NNRTI only V106M E138A 3TC ABC NVP EFV 26 (26)
CT NNRTI only K103N V106M ZDV 3TC EFV ABC 39 (40)
CT NNRTI only M230L ZDV 3TC EFV 21 (21)
CT NNRTI only K103N V106M 3TC d4T NVP TDF EFV 36 (36)
CT NRTI and NNRTI M184V G190S ZDV 3TC EFV 48 (56)
ABC, abacavir; d4T, stavudine.
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Additionally, a MEMSCap substudy on a subset of 61 young people (n= 31 SCT, n= 30 CT) showed a
median (IQR) number of bottle openings per week of five (4–5) in the SCT arm and seven (6–7) in the CT
arm. This suggested that there was good adherence to the protocol. When investigating the percentage of
bottle openings by day, the SCT arm had < 20% of bottle openings on Saturday and Sunday and > 80%
on Monday–Friday, whereas the CT arm had > 80% of bottle openings on each day (Figure 8).
Finally, there was a significantly higher MCV in the CT arm than in the SCT arm at each follow-up visit
after randomisation (p≤ 0.01) (see Table 11 and Figure 7), indicating that young people in the CT arm
were taking ART. A raised MCV has been associated with ZDV and, when investigating the differences
in MCV between arms in young people without ZDV in their ART regimen, there was no significant
difference between arms. This suggests that young people in the CT arm had a higher intake of ART per
week than young people in the SCT arm.
Acceptability
Of 61 young people randomised to SCT who completed the end-of-trial acceptability questionnaire, 58
(95.1%) said that they thought that stopping ART at the weekends made things either a little easier or a
lot easier than taking continuous ART.
A comparison between what young people randomised to SCT found difficult before the trial and what
they found difficult during the trial revealed that young people found it significantly easier to go out with
their friends during the trial than before the trial (p= 0.001).
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FIGURE 8 Bar graph comparing the proportion of days MEMSCap opened between arms.
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Safety
Twenty children had a total of 27 grade 3 or 4 AEs (SCT: 13 episodes in eight young people; CT:
14 episodes in 12 young people) up to the week 48 assessment. There were five treatment-modifying
AEs (SCT, n= 1; CT, n= 4) and two new CDC stage B events (SCT, n= 1; CT, n= 1). There were fewer
ART-related AEs in the SCT arm, with two episodes in two young people in the SCT arm compared with
14 episodes in 10 young people in the CT arm. There were 13 SAEs in nine young people: seven episodes
in six young people in the SCT arm and six episodes in three young people in the CT arm (Table 16).
The most common type of grade 3 or 4 AE was an abnormal laboratory investigation, of which there were
14 episodes in 14 young people [episodes (young people): SCT 6 (6), CT 8 (8)]. There was no significant
difference in the number of young people with any grade 3 or 4 AE (see Table 16), as well as no
significant difference in the grade 3 or 4 AE rate ratio, both before (p= 0.886) and after (p= 0.720)
adjustment for stratification factors (Table 17).
Fewer young people had an ART-related AE in the SCT arm than in the CT arm (2 vs. 10; p= 0.033).
There were fewer ART-related AEs in the SCT arm both before (p= 0.017) and after (p= 0.018) adjusting
for stratification factors (Table 18).
There were no significant differences between arms in how many young people had treatment-modifying
AEs, with just five treatment-modifying events in the first 48 weeks (SCT, n= 1; CT, n= 4; p= 0.369)
(Table 19).
There were no significant differences between arms in how many young people had SAEs (p= 0.331).
Additionally, there were no significant differences between arms in the rate ratio, both before (p= 0.836)
and after (p= 0.979) adjustment for stratification factors (Table 20).
The results were presented as an oral late breaker presentation at the Conference for Retroviruses and
Opportunistic Infections in February 2015 (see Appendix 4).45 Karina Butler was also interviewed at
the conference.46
TABLE 16 Summary of AEs up to the week 48 assessment
Type of AE
Episodes (young people)
p-valueaSCT CT Total
Grade 3 and 4 AEs 13 (8) 14 (12) 27 (20) 0.480
Treatment-modifying AEs 1 (1) 4 (4) 5 (5) 0.369
ART-related AEs 2 (2) 14 (10) 16 (12) 0.033
New CDC stage B events 1 (1) 1 (1) 2 (2) 1.000
New CDC stage C events 0 (0) 0 (0) 0 (0) 1.000
SAEs 7 (6) 6 (3) 13 (9) 0.331
a Fisher’s exact test.
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TABLE 17 All grade 3 and 4 clinical or laboratory AEs up to the week 48 assessment
Grade 3 and 4 AEs
Episodes (young people)
p-valueSCT CT Total
Laboratorya 6 (6) 8 (8) 14 (14)
Blood alkaline phosphatase increased 0 (0) 1 (1) 1 (1)
Blood bilirubin increased 1 (1) 0 (0) 1 (1)
Blood calcium decreased 1 (1) 0 (0) 1 (1)
Blood glucose decreased 1 (1) 0 (0) 1 (1)
LDL cholesterol increased 1b (1) 1b (1) 2 (2)
Neutrophil count decreased 2 (2) 6 (6) 8 (8)
Infections and infestations 3 (2) 1 (1) 4 (3)
Appendicitis 0 (0) 1 (1) 1 (1)
Gastroenteritis 1 (1) 0 (0) 1 (1)
Infective exacerbation of bronchiectasis 1 (1) 0 (0) 1 (1)
Measles 1 (1) 0 (0) 1 (1)
Nervous system disorders 2 (2) 1 (1) 3 (3)
Headache 1 (1) 0 (0) 1 (1)
Hemiparesis 1 (1) 0 (0) 1 (1)
Collapse/suspected seizure 0 (0) 1 (1) 1 (1)
Skin and subcutaneous tissue disorders 0 (0) 1 (1) 1 (1)
Lipohypertrophy 0 (0) 1 (1) 1 (1)
Surgical and medical procedures 0 (0) 2 (2) 2 (2)
Contusion 0 (0) 1 (1) 1 (1)
Inguinal hernia repair 0 (0) 1 (1) 1 (1)
Neoplasms benign, malignant and
unspecified (including cysts and polyps)
1 (1) 0 (0) 1 (1)
Kaposi’s sarcoma AIDS related 1 (1) 0 (0) 1 (1)
Psychiatric disorders 0 (0) 1 (1) 1 (1)
Suicidal ideation 0 (0) 1 (1) 1 (1)
Reproductive system and breast disorders 1 (1) 0 (0) 1 (1)
Gynaecomastia 1 (1) 0 (0) 1 (1)
Total grade 3 and 4 AEs 13 (8) 14 (12) 27 (20) 0.480c
Rate per 100 person-years (95% CI) 12.7 (7.4 to 21.9) 13.7 (8.1 to 23.1) 13.2 (9.1 to 19.3)
Rate ratiod (95% CI) 0.93 (0.36 to 2.43) 1.00 (–) – 0.886
Adjustede rate ratio (95% CI) 0.84 (0.32 to 2.17) 1.00 (–) – 0.720
a Some laboratory AEs were not reported from sites but instead were detected on inspection of the data. The table
includes all occurrences of an increase in grade from baseline. If a marker maintained a grade of AE on consecutive
visits, only one (the highest) grade is reported. If the marker returned to grade 0 then went on to be a higher grade,
these are considered to be two distinct episodes of the event.
b Grades defined on fasting samples. Two young people (n= 1 CT, n= 1 SCT) were not fasting when these events
were reported.
c Fisher’s exact test comparing number of children, not number of events.
d Incident rate ratio from the Poisson regression model with CT as the reference category.
e Adjusted for the stratification factors (age range, African site and African site × age range interaction).
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TABLE 18 All ART-related AEs up to the week 48 assessment
ART-related AEs
Episodes (young people)
p-valueSCT CT Total
Investigationsa 0 (0) 2 (2) 2 (2)
Transaminases increased 0 (0) 2 (2) 2 (2)
Reproductive system and
breast disorders
1 (1) 2 (2) 3 (3)
Gynaecomastia 1 (1) 2 (2) 3 (3)
Nervous system disorders 0 (0) 2 (2) 2 (2)
Dizziness 0 (0) 1 (1) 1 (1)
Headache and syncope 0 (0) 1 (1) 1 (1)
Skin and subcutaneous tissue disorders 0 (0) 5 (5) 5 (5)
Lipodystrophy acquired 0 (0) 5 (5) 5 (5)
Pregnancy, puerperium and
perinatal conditions
1 (1) 1 (1) 2 (2)
Abortion spontaneous 1 (1) 1 (1) 2 (2)
Blood and lymphatic system disorders 0 (0) 1 (1) 1 (1)
Neutropenia 0 (0) 1 (1) 1 (1)
Psychiatric disorders 0 (0) 1 (1) 1 (1)
Suicidal ideation 0 (0) 1 (1) 1 (1)
Total ART-related AEs 2 (2) 14 (10) 16 (12) 0.033b
Rate per 100 person-years (95% CI) 1.96 (0.49 to 7.83) 13.68 (8.10 to 23.10) 7.82 (4.79 to 12.77)
Rate ratioc (95% CI) 0.14 (0.03 to 0.71) 1.00 (–) – 0.017
Adjusted rate ratiod (95% CI) 0.15 (0.03 to 0.73) 1.00 (–) – 0.018
a Some laboratory AEs were not reported from sites but instead were detected on inspection of the data. The table
includes all occurrences of an increase in grade from baseline. If a marker maintained a grade of AE on consecutive
visits, only one (the highest) grade is reported. If the marker returned to grade 0 then went on to be a higher grade,
these are considered to be two distinct episodes of the event. If the included laboratory event was within 30 days before
a change in ART because of toxicity, then it is included in this table.
b Fisher’s exact test comparing number of children, not number of events.
c Incident rate ratio from the Poisson regression model with CT as the reference category.
d Adjusted for the stratification factors (age range, African site and African site × age range interaction.
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TABLE 20 Serious adverse events (reviewed by the ERCa) from randomisation to the week 48 assessment
SAEs
Episodes (young people)
p-valueSCT CT Total
Young people randomised, n 99 100 199
SAEs
Fatal 0 (0) 0 (0) 0 (0)
Life-threatening 0 (0) 1 (1) 1 (1)
Hospitalisation 5b (4) 4 (3) 9 (7)
Causing disability 0 (0) 0 (0) 0 (0)
Congenital abnormality/
birth defect
0 (0) 0 (0) 0 (0)
Other medical conditions 2 (2) 1 (1) 3 (3)
Pregnancya 1 (1) 4 (4) 5 (5)
Total SAEsc 7 (6) 6 (3) 13 (9) 0.331d
SAE rate per 100 person-years
(95% CI)c
6.85 (3.26 to 14.37) 5.86 (2.63 to 13.05) 6.36 (3.69 to 10.95)
Rate ratioe (95% CI)c 1.17 (0.26 to 5.26) 1.00 (–) – 0.836
Adjusted rate ratiof (95% CI)c 1.02 (0.22 to 4.77) 1.00 (–) – 0.979
ERC, Endpoint Review Committee.
a Pregnancies not reviewed.
b One patient had measles but a series of related events (acute gastroenteritis and probable laryngotracheobronchitis) led
to the hospitalisation.
c Not including pregnancies in totals or rates.
d Fisher’s exact test comparing the numbers of young people with any SAE (not the numbers of SAEs).
e Incident rate ratio from the Poisson regression model with CT as the reference category.
f Adjusted for the stratification factors (age range, African site and African site × age range interaction).
TABLE 19 All AEs leading to treatment modification up to the week 48 assessment
AEs
Episodes (young people)
p-valueaSCT CT Total
Young people randomised, n 99 100 199
AEs leading to switch in
NRTI/NNRTI backbone
1b (1) 4 (4) 5 (5)
AEs leading to break in treatment 0 (0) 0 (0) 0 (0)
AEs leading to change in strategy
from SCT to CT
1b (1) 0 (0) 1 (1)
Total AEs leading to treatment
modification
1 (1) 4 (4) 5 (5) 0.369
a Fisher’s exact test.
b Same event led to young person discontinuing EFV and therefore having to change strategy to CT as per protocol.
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Chapter 4 Substudy results
Biomarkers substudy
The results for the linear regression model for each biomarker are presented in Table 21. At 48 weeks,
the only inflammatory biomarker that showed a borderline significant difference between the arms was
D-dimer (p= 0.048), with lower (favourable) levels seen in the SCT arm at week 48.
TABLE 21 Results from the linear regression models for each inflammatory biomarker
Biomarker
Regression at 48 weeks Regression at 96 weeks
n
Estimate for SCT relative
to CT (95% CI) p-value n
Estimate for SCT relative
to CT (95% CI) p-value
CRP 186 –0.254 (–0.725 to 0.216) 0.288 85 –0.051 (–0.738 to 0.636) 0.882
SAA 186 –0.102 (–0.612 to 0.409) 0.694 85 0.170 (–0.525 to 0.866) 0.628
SICAM-1 186 0.039 (–0.099 to 0.177) 0.579 85 –0.044 (–0.221 to 0.134) 0.627
SVCAM 186 0.028 (–0.099 to 0.156) 0.660 85 –0.016 (–0.182 to 0.150) 0.845
IL-10 185 –0.073 (–0.254 to 0.109) 0.431 85 –0.001 (–0.225 to 0.223) 0.992
IL-6 184 –0.051 (–0.268 to 0.166) 0.641 85 0.028 (–0.294 to 0.350) 0.865
IL-8 185 –0.230 (–0.548 to 0.087) 0.154 85 –0.125 (–0.606 to 0.356) 0.607
MCP-1 185 –0.087 (–0.186 to 0.011) 0.084 85 0.055 (–0.093 to 0.202) 0.463
VEGF 185 –0.154 (–0.367 to 0.059) 0.156 85 0.077 (–0.301 to 0.454) 0.688
IL-1RA 186 0.002 (–0.200 to 0.204) 0.985 85 0.059 (–0.259 to 0.376) 0.715
E-selectin 186 –0.036 (–0.145 to 0.072) 0.509 85 0.078 (–0.073 to 0.229) 0.307
P-selectin 186 –0.039 (–0.224 to 0.145) 0.676 85 –0.033 (–0.281 to 0.215) 0.792
ICAM-3 186 0.051 (–0.054 to 0.155) 0.340 85 –0.025 (–0.189 to 0.140) 0.765
TM 186 0.034 (–0.051 to 0.119) 0.432 85 0.090 (–0.044 to 0.223) 0.184
Angiopoietin-1 186 –0.064 (–0.364 to 0.237) 0.677 85 0.096 (–0.400 to 0.592) 0.701
Angiopoietin-2 186 0.037 (–0.056 to 0.130) 0.434 85 0.131 (–0.081 to 0.343) 0.222
D-dimer 181 –0.488 (–0.970 to –0.005) 0.048 82 –0.501 (–1.245 to 0.244) 0.184
TF 184 0.019 (–0.042 to 0.081) 0.535 85 0.035 (–0.080 to 0.150) 0.545
CRP, C-reactive protein; ICAM-3, intercellular adhesion molecule 3; IL-1RA, interleukin 1 receptor antagonist;
IL-6, interleukin 6; IL-8, interleukin 8; IL-10, interleukin 10; MCP-1, monocyte chemoattractant protein 1;
SAA, serum amyloid A; SICAM-1, soluble intercellular adhesion molecule 1; SVCAM, soluble vascular cell adhesion
molecule; TM, thrombomodulin; VEGF, vascular endothelial growth factor.
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Immunology substudy
CD45 naive and memory cells were collected at baseline and week 48 from 119 individuals (SCT, n= 59;
CT, n= 60) and CD8 naive and memory cells were collected at baseline and week 48 from 50 individuals
(SCT, n= 24; CT, n= 25). The results from linear regression models of naive/memory cell ratios are
provided in Table 22. There were no significant differences between arms at week 48 with respect to the
ratios of naive/memory cells. The closest to significance was the ratio of CD8RA/RO (p= 0.135).
When fitting linear regression models with the outcome variable being naive or memory cells
independently and not as part of a ratio, we also found no significant differences between arms
(Table 23).
TABLE 22 Results from linear regression models for each naive/memory cell ratio at 48 weeks after randomisation
Naive/memory cell ratio Estimate for SCT relative to CT (95% CI)a p-value
Log(CD45RA/RO ratio) 0.04 (–0.11 to 0.19) 0.600
Log(CD45RA%/RO% ratio) 0.03 (–0.12 to 0.18) 0.658
Log(CD8RA/RO ratio) 0.20 (–0.06 to 0.46) 0.135
Log(CD8%/RO% ratio) 0.19 (–0.08 to 0.45) 0.162
a Adjusted for baseline ratio value.
TABLE 23 Results from linear regression models for naive or memory cells independently at 48 weeks
after randomisation
Naive or memory cells Estimate for SCT relative to CT (95% CI)a p-value
CD45RA 19.73 (–40.77 to 80.24) 0.520
CD45RA% 0.72 (–1.30 to 2.74) 0.483
CD45RO 10.88 (–26.20 to 47.96) 0.562
CD45RO% –0.17 (–1.61 to 1.26) 0.809
CD8RA 76.86 (–30.06 to 183.78) 0.155
CD8RA% 3.05 (–1.87 to 7.97) 0.219
CD8RO –2.51 (–82.18 to 77.15) 0.950
CD8RO% –0.10 (–0.34 to 0.13) 0.387
a Adjusted for baseline ratio value.
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Virology substudy
In total, 194 young people attended a screening visit and a week 48 visit during the trial and were therefore
eligible for this analysis (SCT, n= 98; CT, n= 96). Two young people in the CT arm who had their original
blood tests using an assay with a lower cut-off of > 20 copies/ml could not be retested with an ultrasensitive
assay, one because there was no sample available and the other because the sample was of an insufficient
volume. However, all other individuals had samples tested using an assay with a lower cut-off of
≤ 20 copies/ml (SCT, n= 98; CT, n= 94). Fifteen individuals had a VL of ≥ 20 copies/ml at screening
(or week 0 if the screening visit sample was unavailable), seven from the SCT arm and eight from the CT
arm. At week 48, 27 (14.1%) young people had a VL of ≥ 20 copies/ml (SCT, n= 13; CT, n= 14); as
expected, this is a slightly higher proportion of individuals than had a VL of ≥ 50 copies/ml (Table 24).
The estimated proportion of individuals with a VL of ≥ 20 copies/ml at 48 weeks was 13.3% in the SCT
arm and 14.9% in the CT arm, giving an estimated difference in proportion between arms (SCT –CT) of
1.6% in favour of SCT (90% CI –9.9% to 6.6%; p= 0.836) (Table 25). The upper bound of this difference
lies well below the 12% non-inferiority margin (Figure 9), which is interesting to note, although the trial
was not powered to investigate the difference in the proportion of individuals with a VL of ≥ 20 copies/ml.
Of the 15 young people with a baseline VL of ≥ 20 copies/ml, only one (CT arm) developed virological
failure during the first 48 weeks of the trial. This indicates that a VL of ≥ 20 copies/ml but < 50 copies/ml at
baseline is not predictive of virological failure within 48 weeks.
TABLE 24 Summary of individuals included in the virology substudy and summary by week of individuals with a VL
of ≥ 20 copies/ml
SCT CT Total
Number of individuals with screening (or week 0)
and week 48 readings
98 96 194
Number of individuals with ultrasensitive assay data
available at screening (or week 0) and week 48
98 94a 192a
≥ 20 copies/ml at baseline, n (%) 7 (7.1) 8 (8.5) 15 (7.8)
≥ 20 copies/ml at week 48, n (%) 13 (13.3) 14 (14.9) 27 (14.1)
Compared with number of individuals with a single
VL of ≥ 50 copies/ml at week 48, n/N (%)
8/98 (8.2) 8/96 (8.3) 16/194 (8.2)
a One individual did not have a sample available to test with an ultrasensitive assay. One individual had a sample available
but there was an insufficient volume in the sample to test with an ultrasensitive assay.
Shading indicates that result came from the primary analysis rather than the virology substudy analysis.
TABLE 25 Estimated difference between arms in the proportion of young people with a VL of ≥ 20 copies/ml at the
week 48 visit
Treatment arm
Number of young people with
a VL > 20 copies/ml at week 48 Estimated proportion 90% CI p-valuea
CT 14 0.149 0.092 to 0.223
SCT 13 0.133 0.080 to 0.203
Difference (SCT –CT) –0.016 –0.099 to 0.066 0.836
a Fisher’s exact test.
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Finally, a comparison between arms of the number of young people with a VL of ≥ 20 copies/ml at week 48
who were virally suppressed (VL of < 20 copies/ml) at screening (or week 0) showed that 12 out of 91
(13.1%) young people in the SCT arm who were virally suppressed (VL of < 20 copies/ml) at screening (or
week 0) had a VL of ≥ 20 copies/ml at 48 weeks, and 12 out of 86 (14.0%) young people in the CT arm
who were virally suppressed (VL of < 20 copies/ml) at screening (or week 0) had a VL of ≥ 20 copies/ml at
48 weeks (Table 26).
Table 27 and Figure 10 show that the difference between arms (SCT –CT) in the proportion of young
people with VLs of < 20 copies/ml at baseline and ≥ 20 copies/ml at week 48 was 0.8% in favour of SCT
(90% CI –9.2% to 7.7%; p= 1.000).
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SCT better CT better
FIGURE 9 Estimated difference between arms in the proportion of young people with a VL of ≥ 20 copies/ml at the
week 48 visit.
TABLE 26 Distribution of VLs at the screening (week 0) visit and the week 48 visit by arm
VL of < 20 copies/ml at baseline VL of ≥ 20 copies/ml at baseline
SCT arm
VL of < 20 copies/ml at week 48 79 6
VL of ≥ 20 copies/ml at week 48 12 1
CT arm
VL of < 20 copies/ml at week 48 74 6
VL of ≥ 20 copies/ml at week 48 12 2
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Qualitative substudy
Summary of key findings
The qualitative study was well received with good recruitment overall (although difficult in the UK, as
described earlier) and retention of trial participants throughout the longitudinal design. Many of the young
people talked at great length during the interviews and mentioned that they enjoyed the opportunity to speak
in relative freedom, and in confidence, about topics that they may otherwise be quiet about in their daily lives.
These ranged from their relationships with their family, friends and school staff to their communication with
clinicians and trial staff. Encouragingly, most participants greatly valued their relationships with their clinicians
and appreciated the care and support that they received. However, they did at times feel under pressure to
present as ‘an ideal patient’ to their clinicians and this was sometimes an inhibiting factor that restricted their
communication in the clinic when they were having difficulties or doubts about their health and treatment.
TABLE 27 Estimated difference in the proportion of young people with a VL of ≥ 20 copies/ml at the week 48 visit
who had a VL of < 20 copies/ml at baseline
Treatment arm
Number of young people with a
VL of ≥ 20 copies/ml at week 48 Estimated proportion 90% CI p-valuea
CT 12 0.140 0.083 to 0.216
SCT 12 0.132 0.078 to 0.205
Difference (SCT –CT) –0.008 –0.092 to 0.077 1.000
a Fisher’s exact test.
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FIGURE 10 Estimated difference in the proportion of young people with a VL of ≥ 20 copies/ml at the week 48 visit
who had a VL of < 20 copies/ml at baseline.
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In relation to the trial overall, participants described a positive SCT experience and a preference for SCT
and those on SCT wished to continue with their new regimen, suggesting that SCT was acceptable to
most participants in the intervention arm. However, they also described challenges adapting to SCT in the
short term. Young people from both arms discussed having initial anxieties about the impact of SCT on
their health and adherence patterns, but these concerns decreased over the first few months of the trial.
It is important, therefore, to consider how their experiences illustrate some of the risks involved for patients
adapting to SCT and the need for tailored support that should accompany any switch to SCT, to which we
return throughout this report.
Once young people had adapted to the new routine, SCT encouraged better adherence during the
treatment-taking days and eased the pressure to carry and remember medication, thus enabling them to
carry out a range of weekend activities. Nonetheless, although described as ‘exemplary adherers’ because
of having an undetectable VL, participants did report missing doses occasionally and intermittently, but
commonly decided that their stable VL results indicated that it was not necessary to report missed doses or
‘slippages’ to their clinician. Similarly, young people from both randomised arms reported frequent and
sometimes disabling treatment side effects that had been difficult to voice in the clinic. Participants also
reported that such side effects were not felt on the days when they did not take their medication.
Overall, the findings suggest that SCT has the potential to encourage more candid discussions about
adherence ‘slippages’, missed doses and side effects and how treatment demands can be managed
alongside young people’s other priorities. In the sections that follow we explore these issues in more detail
and illustrate the study results with direct quotations from participants. We have chosen to use only
randomised arm and country of origin as identifiers for the quotations. This is to protect the anonymity
and confidentiality of the small sample, but also because we did not find significant differences in
responses by either gender or sexuality.
In our analysis we found little difference by site or country. Although there is a reasonable distribution of
quotations from across the three countries, there are slightly more from the US site. This reflects the
difference in linguistic and cultural practices in how ideas are articulated, with the US and UK data lending
themselves most easily to short quotations that encapsulate ideas and experiences whereas in the Uganda
data a similar idea may emerge over a few pages of a transcript.
‘I was taking a break yet I was not used to that’: pre-trial understandings,
fears and hopes
Although participants were keen to take part in the BREATHER trial, throughout the course of the study
we found that this did not necessarily equate with an enthusiasm for trying SCT. At the beginning of the
study, in the first phase of interviews, there was a vocal minority of participants who told us about their
eagerness to take part in the research. A number of them described hoping and praying to be randomised
into the SCT arm. One participant explained the appeal of SCT:
It’s like when you are working and you don’t get a break you get tired. OK sometimes I don’t know
but it is all about like resting.
Uganda, CT arm
They also reported wanting to help their peers and co-operate with their clinicians in their efforts to find
better therapies for them.
However, in later interviews a significant proportion of participants voiced how they had been initially
reluctant about the intervention. They explained to us that they had chosen not to express these concerns
when they were being consented into the trial. This reticence suggests that they may have been hesitant
to talk to anyone about any doubts about taking part in the trial for fear of ‘disappointing’ those in their
health-care team. They felt instead that they could be open during the qualitative interviews, as trust had
been built throughout the course of the study. They also viewed the qualitative research team as being
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independent from the clinic and trial teams. Furthermore, their initial concerns had been balanced against
the trust that they had in their clinicians and their belief that their health-care workers would not endanger
them in any way. In the Ugandan site significant importance was invested by participants in the
‘conclusions’ reached by the pilot component of the trial. Without necessarily discussing this directly with
clinicians, many interpreted this to mean that the safety question had already been answered:
I also first said to myself ‘what is going on’ when they tell us to stop drugs . . . until she told me that it
was a research they had piloted earlier. This means we are not the first ones since they had done
it before.
Uganda, SCT arm
Overall, excellent efforts were made to ensure that participants understood the objectives and methods of
the BREATHER trial and all of the young people interviewed understood what SCT involved. However,
some of the young people, particularly in the Ugandan site, appeared to have a limited understanding of
the study around the time of randomisation and there was also some confusion regarding the distribution
of the days (‘on’ vs. ‘off’ treatment) for those randomised to SCT. This signals the importance of repeated
explanations for young people in trials that rely on their behavioural change and has implications for the
potential future roll-out of SCT, which will be discussed in the concluding section of the report.
Some of the key concerns expressed by participants before randomisation, as well as by those eventually
randomised to the SCT arm, included fears that SCT could actually be dangerous for their health and
‘undo’ the efforts that they had put into sustaining good levels of adherence to ART and keeping their VL
undetectable. Having been consistently told to always take their HIV treatment every day, SCT disrupted
the message of continuous adherence that they had become used to:
I thought that it [SCT] would be harmful . . . Because I was taking a break yet I was not used to that.
Uganda, SCT arm
Some were also worried that SCT could jeopardise their adherence routine as they might forget the days
when they were supposed to take their medicines and those when they were meant to stop or they might
misunderstand instructions or become confused and make mistakes:
Those on the short cycle arm may continue missing drugs even after the 2 days’ break thinking that
they have to miss drugs sometimes.
Uganda, CT arm
Again, they were concerned that mistakes could also cause damage to their health: they were not able to
predict how they as individuals would behave or how their bodies would react. These thoughts were
common and are illustrated by this participant who shares the reflections he had prior to randomisation:
[It] was bothering me just a little bit to take off two days but then again it wasn’t . . . I might miss an
extra day, because then I might be scared that something might go on and my body might change a
certain way or something.
USA, CT arm
Nonetheless, participants also talked about their initial hopes for the trial and sometimes juggled both
concerns about SCT and excitement about its potentially positive ramifications. They anticipated that SCT
would be convenient because it could enable them to engage in various social, study or work activities
by relieving them of the pressures of carrying and remembering to take medication. In some cases,
however, the relief came from the fact that SCT would make it easier to conceal their treatment taking,
hence their HIV status, from others.
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This signalled how difficult adherence may be for young people, particularly those who have not disclosed
their status beyond their clinic and carers:
I am the only one taking treatment at home . . . Children at home normally ask me why I take
treatment day to day and I tell them that I have a sickness. So in case I break they may not know that
I am still on treatment.
Uganda, SCT arm
Importantly, for many participants, SCT, and the BREATHER trial more generally, also symbolised the
potential for scientific progress in relation to ARVs. Hope was widely felt: the possibility of having 2 days
off treatment may herald a foreseeable future when they could take even less medication or when there
may be a cure for HIV:
It brings hope that time will come and you stop taking even the one pill and [that one day] completely
stop taking drugs.
Uganda, CT arm
Notably, many of the participants could remember a time in their childhood when they were taking larger
numbers of pills at different times each day. SCT hence represented a further step along a progressive
trajectory towards better HIV therapy, which is particularly valuable for young people who are faced with a
lifetime of treatment taking:
The thought of having to take something for the rest of your life for 7 days a week it’s kind of nerve
racking, but when you know that you have that break it’s better . . ., it tells the person that
there’s hope.
USA, SCT arm
‘If you put your mind to it, anything is possible’: early experiences of the
BREATHER trial
Many participants told us that whatever concerns they may have had about taking part in the trial (or
being randomised to the SCT arm) eased off as they saw that SCT was working and their blood tests
results continued to look promising. As the perceived dangers of the intervention did not materialise, they
could ‘relax’ into their new regimen. The increasing confidence that they had in SCT may also be the
reason why they felt that it was possible to discuss whatever early anxieties they may have had during the
second set of interviews.
Nonetheless, it is important to note that adaptation to SCT presented them with challenges for some time:
Oh, that was hectic . . . when I first started the study, I think the first week I think I took it on a day
that I wasn’t supposed to take it because I’m so used to it. But now I’m used to it.
USA, SCT arm
Once again, these challenges are better understood in the context of the emphasis placed so far on the
importance of daily treatment:
Because being so used to taking it 7 days a week and then now they’re saying I can take 2 days off,
it’s like a slight change and if you don’t get your mind focused . . . basically it’s like when you’re so
used to something and then you’re trying to change it, it takes time. But then if you really put your
mind to it then you can, anything is possible.
USA, SCT arm
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Short-cycle therapy also temporarily affected some of the participants’ autonomy in treatment taking.
To adapt to their new treatment schedule they had to reverse the independence that they had gained by
managing their own treatment and temporarily ask for the support or supervision of their carers.
Overall, however, all those on SCT reported getting used to their new regimen and even finding that
having 2 days off helped them to stick to their medication for the 5 days when they were meant to take it.
SCT thus worked both as a reminder and as a reward:
It [SCT] gives you the courage to take your drugs daily other than in the other days. Reason being that
you will say that I have missed to take the drugs in these 2 days that means that in the remaining days
I have to be vigilant to take the drugs.
Uganda, SCT arm
Importantly, the discussions about any problems that they may have encountered with SCT stimulated
participants to talk to us about their adherence issues more generally. From these rich sets of narratives we
were able to identify two fundamental challenges that young people living with HIV in all three sites faced
within and beyond the trial period: missing doses and medication side effects.
‘I am scared of getting caught up in my lie’: challenges to
self-reported adherence
The qualitative study found that there were widespread patterns of missed ARV doses both before and
during the trial. Most participants talked about missing doses from time to time, with some describing
substantial periods of non-adherence that had occurred at different points in the past. Notably, however,
few of those who had missed doses had discussed these instances with their clinician and this was often
because participants felt that this could somehow damage their reputation in the clinic as an ‘exemplary
adherer’ and harm their relationship with their health-care team.
Compared with the study questionnaire (see Appendix 5), the qualitative study found much higher levels
of non-adherence in participants’ accounts. This highlights the importance of in-depth interviews as spaces
where participants may be able to disclose missed doses more comfortably as they are able to also explain
the challenges that they face in achieving consistent adherence. Additionally, such findings also help us to
better contextualise the broader trial results and the methodological implications of this will be discussed
further in the discussion section (see Chapter 5).
Many participants talked about how they made their own assessment of the risk involved in missing doses
and, crucially, relied on their blood tests results to decide if it was worth mentioning to their clinician that
they had skipped their medication. VL results represented the most accurate version of their health and at
once functioned as ‘truth’ tests that could reveal their behaviour. Given that young people considered that
telling their clinician about any missed doses would inevitably damage their reputation as an excellent
patient, they interpreted an undetectable VL result as meaning that making any disclosure of missed doses
was an unnecessary risk:
I try not to hide anything, it’s just that I probably feel like a smidge ashamed . . . I don’t like hurting or
disappointing anybody . . . because I have told them if they asked, but if they didn’t ask then and
I find out my viral load was undetectable then I just let out a sigh of relief and just keep going.
USA, SCT arm
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At the same time, despite the trust that young people placed in their VL results, the practice of
non-disclosure could be filled with anxiety:
I’m really scared of disappointing them and making them upset so sometimes I will have times . . .
where I wouldn’t say anything especially if I know it’s more than the usual . . . I’m scared of getting
caught up in my lie and saying ‘oh, well, I haven’t missed any this month’ and my VL and my CD4
comes back terrible, you know?
USA, SCT arm
In addition, being ‘undetectable’ was a source of pride for young people. They described being praised by
clinicians and they often valued having a reputation as an ‘exemplary adherer’, which in some ways
counteracted the ‘damaged identity’47–49 that often accompanied their HIV status. Although considered to
be coping excellently by clinical staff, in the qualitative study some young people revealed that they felt
unable to tell their clinicians about the struggles that they had with their treatment or HIV status.
Unfortunately, their wish to not damage their reputation could constrain their capacity to access support.
It is important here to underscore that many of the study participants were able to talk about their HIV
status only in the clinic and, to varying degrees, within their family. Against the background of the
centrality that these social spaces hold in their young lives, the fear of disappointing others or being seen
as a failure could be particularly acute.
On the other hand, some participants felt that SCT helpfully ‘legitimised’ missing doses, in a structured
way. They were reassured by the trial that their medication had continued to be effective even if they had
not been able to adhere 100% to their daily regimen:
If you don’t have a break you may forget to take drugs like on a Saturday or Sunday but if you are
supposed to have a break it is acceptable.
Uganda, SCT arm
Indeed, the very fact that SCT was being tried in the BREATHER trial was an indicator for participants that
their issues with taking treatment everyday were implicitly understood by clinicians and that a solution was
being sought to support them with their adherence. This can be seen as a significant benefit in terms of
potentially improving communication in the clinic against the background of some of the reputation-
related pressures highlighted so far.
‘I just feel like I am not really there’: significance of antiretroviral treatment
side effects
The young people in the study also reported common and significant side effects of their EFV-based
combination therapy. The main symptoms that they talked about were dizziness, feeling ‘spaced out’ or
‘high’, not being able to concentrate well and not ‘feeling quite themselves’. Some also reported stomach
cramps shortly after taking their pills. This appears to be in line with clinical data on EFV50,51 as well as with
extant qualitative research on the side effects of EFV,52 although to our knowledge no data have yet been
published about the experiences of young people on this particular medication.
Importantly, we found that more treatment side effects were discussed in the qualitative study than may
have been reported by participants to their clinician, both before and during the trial. The extent to which
side effects affected those young people in the study who reported them in the interviews varied in terms
of severity and frequency. Some participants talked about how the intensity of their initial symptoms had
diminished some time after having started the EFV-based combination. In addition, not all participants
experienced side effects every time they took their medicine and some talked about the side effects
decreasing within a few hours of taking the pills.
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In most cases, however, side effects interfered with young people’s daily activities at school and work:
Sometimes when I take it I do feel a bit dizzy and if I take it in the morning I have to then walk to
college and I’m feeling a bit ill and I’m finding it a bit hard to concentrate during my lessons.
UK, SCT arm
Some participants discussed having to change the time of day when they took their medicines or adapt
their day-to-day activities, including school classes and work shifts, to cope with side effects:
Well other than the doses at five I tried switching it up, when I was in school I tried switching it to me
taking it in the morning and that wasn’t, I don’t know, I can’t say it wasn’t really such a good idea but
it was just that feeling of being high at school was not the best situation, I don’t like that at all
because I mean I can concentrate it’s just I just feel like I’m not really there . . . I get more clumsy if I’m
under the influence of the medication.
USA, CT arm
One participant described their experience of treatment side effects:
When I asked the doctor she said it was normal and that the drug was strong. That’s why it causes
dizziness. I used to take it while at school but I would feel dizzy. After taking it at 9:30 p.m. I could
not read at 10, 11 p.m. and would not be able to walk properly yet I didn’t want disturb other
children so I would just lie down there . . . because I knew that sometimes I would feel weak that I
couldn’t even stand on the bed.
Uganda, SCT arm
On the whole, side effects were commonly discussed and often appeared to be considerably disabling,
although many of the young people portrayed them simply as an inevitable part of their lives. This may in
part have been shaped by the initial responses of health-care workers, as is the case above.
Worryingly, some of the young people described not having initially identified these symptoms as being
side effects of the medications and perceived instead that the drowsiness and dizziness were part of their
personality. This is an important finding, warranting further investigation for this cohort of people living
with HIV who have been on treatment since before they can remember.
Many may not be able to disentangle the effects of the medication from their own physiological feelings
or they may find it confusing to distinguish between the two, as this participant, who is describing how it
feels when he inadvertently skips a dose, explains:
Interviewer: And when you miss it for a day does it change, does it influence how you’re thinking
about your health or your body?
Young person: No, it actually makes me feel a little better sometimes . . . It feels like I don’t have a lot
of strain on my body when I don’t take my medicine . . . It’s kind of scary in a way.
Interviewer: So why is it scary?
Young person: Well for one reason why because when I take my medicine I feel one way but the
nights that I miss it I feel like my regular self . . .
Interviewer: Which do you prefer, which feeling?
Young person: I actually prefer the medicine feeling because I, because it’s helping me.
USA, CT arm
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We would suggest that some of the participants, especially those who have been coping with these side
effects for a while before the trial, might have chosen not to mention these issues to their clinician if they
had found ways to get by despite the challenges of these effects. Nonetheless, we do not currently know
enough about how such side effects might affect adherence behaviours, considering that young people
may be reluctant to discuss both issues.
‘It’s the best days ever’: successful adaptation to short-cycle therapy
Participants on the SCT arm discussed how SCT had enabled their social life to grow. For some of these
young people, having the weekends off taking medicines meant that they were able to go and spend a
few days with their friends for the first time. SCT allowed them to travel more, sleep at friends’ houses,
visit relatives and go out to parties and clubs without the pressure of carrying, concealing or taking
treatment. One participant described how they felt being on the SCT arm:
I feel so free. You feel free; I can see you are even smiling [laughter].
Uganda, SCT arm
Short-cycle therapy was a major improvement for many participants:
I do not know what it is about those 2 days, but it’s the best days ever . . . I can go somewhere and
not have to worry about taking that pill. Sometimes when I take the pill, my stomach hurts sometimes
. . . but I don’t have to worry about that, and I don’t have to worry about taking this big pill, and I
don’t got to worry about coming home at a certain time and taking it, I don’t got to worry about
getting up and taking it. I’m just free for those 2 days.
USA, SCT arm
Having the weekend off treatment was described not only in terms of having fun and socialising but also
as restful and relaxing:
It’s actually very good because I can actually get some time for me and actually not think of the drugs
as in today I don’t have to take and tomorrow. I also get a day I am free to do whatever I want at any
time I want, go out wherever I want to stay over the weekend and then take them [drugs] when I am
back on Monday. So it’s easier and good.
Uganda, SCT arm
Participants emphasised that the benefits of SCT in part stemmed from reducing the visibility of their HIV
treatment in social situations at the weekends, which minimised the risk of potential deductive disclosure.
This is illustrative of the broader concerns of young people, which may underpin non-adherence on
particular days or during social events. As one participant explained:
Saturday and Sunday are not convenient days for taking the drugs . . . At times it becomes tiresome to
take the drugs everyday because there are times when you are away from home or amongst people
who don’t know about you . . . So whoever sees you becomes eager to know what you are taking or
what you are hiding. In my opinion having to rest is good because sometimes you may be amongst
people like on a Saturday or Sunday but you are not going to take drugs so no one will get to know
about your health. So having to take drugs everyday makes you anxious because you worry about
being seen or being amongst people who do not know you.
Uganda, SCT arm
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Another important element of such a rest was having a break from side effects. Many of the young people
in the study had talked about side effects occurring immediately after taking their pills, hence many
similarly reported not feeling any of the side effects on the days when they did not take treatment. This
provided a valued window of respite:
I don’t get hot flushes on the weekends and I can stay up a little bit longer, because normally when
I take my medicine I get the hot flushes and I get real irritated, where all I want to do is lay down. It’s
like your body starts getting woozy and weak and now on the weekends it’s like, I’m just still full of
energy. So it’s better, much better.
USA, SCT arm
Another helpful aspect of SCT was the motivation that it brought to being stricter about taking treatment
on the 5 days as prescribed. As previously mentioned, participants perceived their weekend off medication
as something to look forward to and this encouraged them the rest of the time. Some also talked about
making even more sure that they took their medicines during the 5 days ‘on’ for fear of missing too many
cumulative doses:
I’d probably have been a bit more cautious because it’s like 3 days you’re missing, three out of seven
instead of, because if you took it six times out of seven, it’s fine, but like you’re already missing 2 days
so I, you kind of get the impression you can’t really miss another one.
UK, SCT arm
What transpired from many of the interviews was that adhering to SCT involved work and commitment,
but that the new therapy regimen was a welcome opportunity that opened up new possibilities. Some
participants were thus recalcitrant about going back to CT, pending the outcome of the trial:
Young person: If they were to, if God forbid but if it came to a point where I had to go back to taking
it 7 days a week I would probably be a little upset. But it would be OK though.
Interviewer: Do you think that would be difficult to adapt back to?
Young person: It will, it will.
Interviewer: What would be hard about it?
Young person: Just the fact that I can’t, it probably won’t be as difficult, I’ll be able to adjust to it very
quickly, but I just won’t have those reward days any more.
USA, SCT arm
However, although a few were clearly enthusiastic about their new treatment schedule, some also talked
about it being ‘more of the same’ as they had no previous issues with taking their medication. They saw
little difference in the new regimen:
Yeah, definitely, like if it’s, I don’t know if it’s helping or not but it really doesn’t impose anything on
me so why not? It’s kind of one of those things, like nothing lost so you might as well . . . It’s just like
a small bit of, it’s a small bit better but then I don’t know how much difference it’s making.
UK, SCT arm
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‘Why should I take it every day?’: participants’ perspectives regarding
short-cycle therapy for other young people
As we have seen, the young people who were randomised to the SCT arm all reported a preference for
SCT after an initial period of adaptation, which supports the results of the clinical trial thus far. However,
many of the participants in the trial also expressed concerns about SCT being potentially challenging for
other young people to manage. They described SCT as ‘better’ rather than ‘easier’ than CT. For those
struggling with their adherence, although there may have been benefits of the breaks, it was considered at
least initially a more confusing regimen to follow.
Many of the study participants, from both trial arms, discussed how the message about the need for
continuous daily adherence at set times had so far been simple and straightforward. Offering young
people the opportunity to take weekend breaks through SCT disrupted the clarity of that message and
may also inadvertently indicate to young people that missing further days and doses is OK:
It might be [dangerous], it might be because some people might see it as like, why should I take it
every day? Maybe I should just go ahead and stop taking every day and skip 2 days or 3 days, just to
give me, just to clean me out or something like that.
USA, CT arm
Many were also concerned about what other HIV-positive young people might do once the trial results are
made public. They frequently mentioned this as a significant worry as they imagined that other young
people might try to ‘do SCT’ on their own, without telling anyone, and cause damage to their health
because they had not understood the preconditions for SCT, including having an undetectable VL and
being on an EFV-based medication combination.
Participants viewed this as a substantial risk that needed to be mitigated with careful communication and
dissemination, as another participant, also in the CT arm, explained:
I do think for some people if they do find out about the information it may be OK if they do it but in
the back of my mind I’m still worried because if some people don’t have, if some people aren’t
undetectable and they try to do the short-cycle therapy that would really affect them and I get worried
about that.
USA, CT arm
Overall, when participants were asked to reflect on what made them good at adherence, perhaps in
comparison to others who they knew, they talked about the importance of a supportive environment, in
the clinic or within the family, that would help them manage their medication. A supportive environment
in this case was characterised by openness and the possibility to report their adherence challenges without
fear of being scolded. Therefore, in the view of participants, other young people who may lack these
various forms of support could find it problematic to switch to a new way of taking their treatment.
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Chapter 5 Discussion
Main study
Children and adolescents find the commitment to taking ART every single day difficult. Previously it has
been accepted that, to achieve optimal virological suppression, > 95% adherence to a daily ART regimen is
necessary.53 Many of the data underlying that assumption were generated in the era before the advent
of today’s more potent regimens, now often incorporating one or more of the longer-acting ARV agents
such as EFV.
We hypothesised that the pharmacokinetic properties of a drug such as EFV might be exploited to permit
very short interruptions in daily ART while effectively maintaining viral suppression, in effect allowing a
break in pill taking without a real break in therapy. Such a strategy, that is, SCT, could reap several
benefits. Allowing breaks in taking medications at particularly difficult times, for example weekends, could
help normalise the life experience for young people, reduce the problem of gradual pill fatigue, reinforce
adherence during the remainder of the week and obtain similar benefits to CT in terms of virological
suppression but with reduced overall drug exposure.
In this study, the non-inferiority of viral suppression in young people on EFV-based first-line ART was
demonstrated for SCT compared with CT.
This global, randomised, Phase II/III study recruited 199 young people across 11 countries. With just over
one-third of participants from Africa, one-fifth from middle-income countries and the remainder from
Europe and the USA, we were able to study the potential utility and applicability of the strategy in diverse
geographical settings. The median age of young people enrolled was 14 years and, in total, 21% were
young adults (aged 18–24 years). The generalisability of the results therefore extends not only to older
children and adolescents but also to the important group of young adults for whom weekend socialising
often leads to missed ARV doses.
The baseline characteristics of participants in the two study arms were well matched. The minor imbalance
in CDC C events, with a greater number in the CT arm, is unlikely to be meaningful given the equivalence
of CD4 counts and percentage at enrolment. A major strength of this study is the excellent follow-up,
with only one participant lost to follow-up before the 48-week assessment and the median duration of
follow-up being 86 weeks, with > 98% of clinic visits attended.
Assuring adherence to the randomised strategy was critical to the integrity of the trial results. If those
randomised to the CT arm elected of their own accord to take breaks in therapy, non-inferiority of SCT
and CT might be shown, but with both arms taking breaks and having similar treatment schedules.
Four independent indicators of adherence to the assigned strategy provided reassurance in this regard.
The results of the self-reported compliance in the SCT arm (95% of weekends off taken), the MEMSCap
substudy (median cap openings 5 for SCT vs. 7 for CT), analysis of MCV levels in ZDV recipients and
self-reported adherence questionnaires in both arms were all consistent in supporting the concept that
young people in the SCT arm had appropriately less ARV exposure than those on CT arm and that young
people were adherent to their assigned strategy.
The overall outcome for young people in the study was excellent, with 93% remaining virally suppressed
to < 50 copies/ml and 97% remaining virally suppressed to < 400 copies/ml. This may well reflect that this
was a selected population, all of whom had a record of good adherence prior to study entry and none
of whom had experienced virological failure. The primary study end point, confirmed VL > 50 copies/ml,
was reached by only six in the SCT arm and seven in the CT arm, representing a 1.2% difference in
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probability of failure in favour of SCT. The study hypothesis was thus confirmed: SCT was non-inferior
compared with CT for viral suppression over 48 weeks.
Although viral suppression was the primary end point of this study, it was equally important to ensure that
there were no other detectable indicators of potential hazard associated with the strategy in terms of
immunological compromise, emergence of viral resistance or inflammatory change. No difference in CD4
counts or CD4%, or in the emergence of major resistance mutations was detected. Although viral sequence
data were not available for four out of 13 participants meeting the primary end point criteria (n= 3 SCT,
n= 1 CT), all four subsequently resuppressed suggesting that the presence of resistance was unlikely.
In a previous CD4-guided long-period interruption trial, the SMART study,22 the unanticipated excess of
cardiovascular events highlighted the importance of HIV infection as an inflammatory state with the
potential for re-emergence of chronic inflammation in the event of treatment interruption. Incorporation of
the biomarker substudy was thus an important component of this trial and provided additional reassurances
with regard to the safety of the strategy.
Study limitations
The BREATHER trial included a selected cohort and was carried out in a very controlled manner, which
means that the results may not be easily generalisable to real life. Young people eligible for enrolment
were those who had never experienced virological failure and who had stable viral suppression, indicative
of good adherence prior to enrolment. To confirm the long-term safety and efficacy of this approach a
longer follow-up period is needed and, for clinical settings where monitoring is less available, larger
pragmatic trials, based on routine clinical practice, are necessary.
Efavirenz was selected based on its pharmacokinetic properties that, despite its low genetic barrier to
resistance, render it relatively resilient and forgiving of short interruptions in therapy. The success of the
strategy may also relate to the fact that standard dose recommendations for EFV may be higher than is
necessary for virological control. The ENCORE 1 study in adults54 demonstrated non-inferiority for EFV
dosed at 400mg/day compared with the standard 600-mg dose, a 30% dose reduction. The BREATHER
trial has shown that the weekly EFV dose can be safely reduced by 2 days a week (29%), with standard
doses delivered over 5 rather than 7 days. The SCT strategy has not been studied and may not be
applicable in situations where lower EFV dosing regimens are used.
Inflammation and immunology substudies
As presented in Chapter 4, with the exception of the D-dimer results, no significant difference was seen
between the trial arms in any of the 19 biomarkers. Patients randomised to SCT had slightly lower D-dimer
levels at week 48 than at baseline, which is reassuring rather than worrying. The panel of biomarkers
selected was comprehensive and these results add further reassurance that SCT is safe.
Similarly there was no evidence that CD4, CD8 or naive and memory subsets were affected by SCT. This
contrasts with the findings reported in the PENTA 11 study,41 in which an interruption of 48 weeks was
associated with marked changes in these parameters. This indicates that, at least for the duration of the
study, there was no apparent inflammatory or immunological impact of SCT using markers that have
previously been shown to be perturbed following treatment interruption.
Virology substudy
Recent evidence suggests that the HIV reservoir, which is not currently assessed with available routine
diagnostic methods, plays an important role in disease progression.55 Markers quantitatively evaluating
residual viraemia56 and functionally assessing the ability of the reservoir to produce replication-competent
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virus57 are therefore emerging as additional necessary tools in patient stratification for prognosis and
optimal management. The aim of the virological substudy was to evaluate the impact of SCT and CT on
the reservoir as assessed by low-level residual viraemia and total HIV-1 DNA levels.
Although there was a slightly higher proportion of individuals with a HIV-1 RNA VL > 20 copies/ml at
week 48 than > 50 copies/ml at week 48, reassuringly the number of young people with a HIV-1 RNA VL
> 20 copies/ml at week 48 was comparable between arms (n= 14 CT, n= 13 SCT). There was no
difference between the arms at baseline when the 20 copies/ml cut-off was used, which in addition was
not predictive of virological failure.
These results indicate that young people in the SCT arm were not at risk of increased low-level viraemia at
the end of the trial.
Qualitative substudy
The findings from the qualitative substudy indicate that those in the SCT arm, after taking some time to
adapt, expressed a preference for taking the weekends off therapy, suggesting that SCT was acceptable to
them. Although promising and preferred by those in the trial to CT, SCT may not, however, be a viable
option for everyone, as even ‘exemplary adherers’ encountered initial challenges in adapting to the new
5 days on/2 days off routine.
Notably, SCT was preferred by the young people in the study in part because it enabled more effective hiding
of their HIV status. As SCT reduces the risk of deductive disclosure through the witnessing of treatment
taking, young people were able to engage in social activities that had previously been complicated by their
desire to keep their HIV treatment and/or status secret. Although positive in the short term, it is of some
concern in the longer term that denial about their HIV status might be perpetuated and disclosure postponed.
At some point, these same young people will be encouraged to disclose their status as they transition to
adulthood and begin their sexual lives. SCT might thus unintentionally support non-disclosure for a group of
people living with HIV who will have to come to terms with disclosure in the not-so-distant future.
The study highlighted patterns of non-disclosure of adherence behaviours that often prevail among young
people living with HIV.58 In addition, our data have illustrated how young people use clinical indicators to
interpret whether or not to share information and to justify non-disclosure, which contributes further
insights to our current understanding. This relates to the limited reporting of missed doses. The lack of
necessity to disclose missed doses appears to be reinforced by the confidence that young people invest in
clinical monitoring; they interpret an undetectable VL as a demonstration that recent missed doses are not
significant and do not need to be reported.
The impact of medication side effects on well-being were also consistently under-reported to clinicians and
possibly within the trial. Some participants had come to perceive these side effects as ‘normal’ and as they
considered them to be inevitable they did not consider it worth bringing them up and discussing them
further. Once again, this illustrates the significant filtering that might be involved in young people’s
conversations with clinic staff. Furthermore, discussion of treatment side effects may also provide valuable
insight into the disparity between the common reporting of these side effects in the qualitative study and
the rare reporting in the trial, where they may not have been described as unusual or severe.
The study participants clearly do not currently discuss many of their ongoing issues around their treatment
and their condition with anyone and try instead to manage by themselves. They gain confidence in not
needing to mention missed doses from the trust that they invest in what an undetectable VL signifies.
This is particularly problematic in terms of their openness with clinicians, the lack of which might lead to
health-related harms if treatment challenges are explored or revealed too late and medical options
restricted. Reinforcing the reputation of young people as ‘exemplary adherers’ may paradoxically function
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as both an encouragement for young people to continue to take their treatment as prescribed and a
disincentive to talk about any problem that might arise, including missed doses and side effects, for fear of
damaging their reputation.
Importantly, therefore, an opportunity is opened up whereby SCT has the potential to signify the beginning
of a change in the conversation around adherence in the clinic, within the family and within the broader
social environments inhabited by young people living with HIV. As a therapy that specifically acknowledges
the adherence challenges that pertain to childhood and adolescence, if framed thoughtfully health-care
staff can use SCT to show a greater contextual understanding about how treatment can be disrupted for
complex reasons. By encouraging more open discussions about ‘slippages’ and how these can be managed,
SCT might be able not only to support improvements in communication between health-care staff and
young people living with HIV but also to lessen the significant blaming and self-blaming that can at times
characterise the experience of those who cannot achieve 100% adherence to ARVs.
The study findings suggest that SCT could be used as a ‘reward’ for those who can manage to adhere well
and this could sustain them on the days when they are supposed to take their medication. In addition, SCT
could also function as an incentive to put more effort into taking treatment and lowering VL for those who
would not currently qualify for SCT. Thoughtful planning and framing of SCT to young people is necessary
for these potential benefits to be realised.
However, study participants felt that SCT could also pose a significant risk to other young people who
might try to take treatment breaks without clinical assessment and monitoring. This is a further reason to
support the need for careful dissemination and communication of the results post trial. Recommendations
for how the intervention and its results are to be communicated beyond the trial will be discussed in the
concluding sections of this chapter.
Most of all, the initial challenges described by so many of the study participants need to be taken into
serious consideration when planning any further interventions based on SCT. The findings suggest that the
initial adaptation period, although different for different participants, was generally only short-lived but
should not be underestimated. Provided that early adjustments are carefully managed and supported,
however, the study has shown that SCT can be successfully transformed into a welcome ongoing
treatment option for young people living with HIV, with great benefits for children’s and adolescents’
personal and social lives.
Study limitations
A key limitation of the study is the population on which these findings are based; trial participants were
arguably initially predisposed to be more accepting of the intervention. However, this is complicated by our
finding that many participants initially agreed to participate in spite of, not because of, the intervention.
So far we have not explored the acceptability of SCT among those who refused to take part in the trial or
those who were not eligible. It would be valuable to address the question of the acceptability of SCT more
broadly and robustly. Although we aim to be able to redress some of these limitations through our
post-trial ongoing data collection, it is important to note that, in the UK, this is quite a heavily
researched cohort.
In making sense of the participants’ accounts, it is also important to highlight that the experience of being
in the trial in itself may have been conducive to better adherence. Some of the findings should therefore
be interpreted with particular caution against the background of the increased support and monitoring
that the young people experienced during the course of the study, particularly in contexts where there
may be little or no access to this kind of monitoring outside the trial period. Equally, it is possible that
some of the early anxieties shared by many participants with regard to the safety of SCT would not arise
for other young people once the trial and follow-up have ended and the results are fully established
and disseminated.
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Conclusions: implications for health care and recommendations
for research
The qualitative study within the BREATHER trial has uncovered and highlighted a number of important
issues that are relevant for the treatment-related support that is needed for this cohort; the trial and
possible subsequent interventions based on SCT; and the direction that future clinical and social research
with this age group should take so that we can better understand and effectively respond to the
challenges at hand.
Implications for supporting adherence among young people living with
human immunodeficiency virus
Our findings point to the predominant need to expand and improve conversations around adherence
issues that young people have with their clinicians, family and peers. Young people’s narratives about
treatment and adherence are characterised by many of the same problematic realities of their adult
counterparts. These include, but are not limited to, fear of stigma, lack of motivation, fear of reprimand,
treatment side effects and the practical hurdles of adhering to a daily regimen.59,60
However, young people also present with particular and unique challenges that pertain to youth, for
example their more absolute dependency on their carers and clinicians, their at times limited knowledge
about their condition and its potential impact on their future lives, but also the acute importance of
socialisation and acceptance by their peers, the restrictions on their capacity for self-management in the
context of school and the household, the common histories of HIV-related loss in the family and the added
pressure of facing a lifetime of treatment from a very young age.61,62
It is therefore paramount that their problems with adherence should not be underestimated or dismissed
as ‘forgetfulness’, ‘irresponsibility’ or a simple lack of awareness of the seriousness of the medical
consequences of poor adherence. Findings from this study reveal the opposite: young people think about
their health a great deal and adherence challenges thus need to be recognised and discussed
transparently, as well as confronted with even more empathy and patience.
We have found that even within this cohort there is a lack of reporting of missed doses, under-reporting of
side effects and a general sense that young people have the need to conceal their problems and devise
alternative strategies on their own, without seeking medical advice or other help from carers, relatives or
peers. These strategies can include relying on VL tests to assess the risks of missing doses, experimenting
with skipping doses to see how much they can miss, adjusting the time when they take their pills to fit in
around other daily activities and coping through these processes without seeking support and at times
while experiencing significant shame about their health-related behaviours and anxieties about their
own health.
Equally, the study results indicate that young people really appreciated the VL testing that they received
during the clinical trial, which has particular implications for any settings (such as Uganda) where testing
frequency may vary significantly between trial and non-trial clinical practice. Furthermore, the convenience
and cost saving attached to reduced monitoring should be weighed against the impact that this may have
on young people’s adherence, especially against the background of their current lack of reporting of
missed doses and the reassurance that many of the participants draw from the test results, which are also
important for their own understanding of HIV infection.
This study contributes valuable qualitative evidence about the significance of side effects experienced by
patients on EFV-based regimens. This will be explored further in future analyses and publications and will
be the subject of a workshop convened in collaboration with CHIVA UK.
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Implications for future short-cycle therapy roll-out
The findings from our study emphasise the importance of incorporating a package of interventions to
accompany any roll-out of SCT to support young people in adapting to this new routine. These
interventions would need to be designed based on the multiple findings from the clinical and qualitative
trial components and subsequently evaluated for further roll-out.
Some preliminary suggestions about what the interventions would need to include can already be made by
looking at the qualitative study results. From a synthesis of the discussions in the interviews, we would
anticipate an adaptation period of 12–18 weeks to be appropriate for young people switching to SCT
from CT, possibly preceded by a 4-week preparation period before switching to ensure understanding and
alleviate any concerns. This could draw on peer support opportunities, with those already on SCT providing
advice and sharing experiences, written case studies or participation in targeted interventions.
Given what we have observed about how young people make decisions about how they engage with their
treatment and decide when and how to take it – and also whether or not to report what they are actually
doing – it is critical that they have a genuine understanding of SCT: what it is and how long it lasts and
continues to work in the body. The provision of education about SCT to young people (and their carers)
would thus be central to any successful roll-out.
One aspect of SCT that would need to be carefully explained is why treatment needs to be missed on
2 consecutive days rather than any 2 days in a week. It would also be beneficial for young people to have
the option of choosing which 2 days are best for them to miss as some of the participants who had
treatment breaks during the weekend mentioned that they may have preferred missing weekdays in light
of their work shifts and school classes.
The study found that young people benefit from the assurance that they derive from clinical monitoring,
which gives them confidence in their state of health and the efficacy of the way that they are taking their
treatment. Hence, we would strongly recommend that a similar practice of VL monitoring to that provided
in the trial is made available for some time if SCT is introduced.
Furthermore, as well as a support intervention around the time of introduction of SCT, we would
recommend that currently available measures of both adherence and side effects should be improved. This
would be of particular importance for young people moving to SCT because of the disruptive potential of
introducing a new regimen, coupled with the possibility that young people may under-report missed doses
so that they are not placed back on CT.
Additionally, as SCT would be provided using an EFV-based combination only, we would recommend that
the significant issues around side effects detailed in this report are taken into greater consideration for all
young people on this medication, but especially for those who may be switched to this particular drug
to start SCT having been previously being treated with different ARVs. Side effects have been shown in
this study to impact on adherence but also on young people’s overall well-being and it is therefore
paramount that they are repeatedly encouraged to discuss them and that any AEs are recorded and
managed with greater care than our findings would currently suggest.
Implications for further research
The qualitative study with young people living with HIV explored the experiences of study participants
during the course of the clinical trial. However, further follow-up research is needed to review responses to
the trial findings among the trial population and, especially, to disentangle the effect of the trial on young
people’s adherence-related behaviours. This would be important to understand both how trial participation
impacts on behaviour in the present and what might be the effects of participation for the long-term
management of HIV in young people on SCT. Furthermore, qualitative research may be needed to
investigate how young people experience, manage and adapt to being put onto SCT when this is rolled
out outside trial conditions. An evaluation of the accompanying support intervention could be integrated
into this qualitative study.
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At the same time it would be vital to investigate how HIV-positive young people outside the trial may
interpret SCT and to explore perceptions, understandings and the potential impact of knowledge about
SCT in the wider HIV population. This evidence would be of help to inform the adherence support
intervention mentioned above, but would also allow any other issues that may arise to be addressed
promptly. Gaining an understanding of initial reactions to SCT would thus aid implementation work that
would be conducted to minimise the risks of inappropriate uptake of SCT by those young people for
whom it may not be clinically feasible. Research with both trial participants and their peers that analyses
responses to and perceptions of SCT would also contribute to the development of any communication/
dissemination tools that would be needed to support the roll-out of SCT as well as contributing to the
design of an appropriate intervention alongside other programmatic expertise with this population.
We would also recommend that the ways in which qualitative analyses are integrated to inform trial
findings could be reviewed. In particular, it will be important to explore novel ways to engage with some
of the differences in findings that have emerged from a comparison of the qualitative and quantitative
data in the BREATHER trial. Findings about both adherence and side effects differ markedly between the
qualitative interviews, the quantitative survey about adherence during the trial and the treatment-related
AEs reported in the clinical database. We do not consider these differences in data sets to indicate greater
or lower levels of accuracy of the findings generated from each method. Rather, we suggest that these
potential differences might be usefully triangulated and integrated in further study designs, including
during the course of trials, to obtain a more comprehensive picture of the adherence-related behaviours
and experiences of young people on HIV treatment.
Finally, the findings from our study clearly indicate that further and urgent research is needed to improve
our understanding of the experiences of young people on EFV-based combination medication. There is a
dearth of qualitative research on the side effects of this medication and no current research on how it may
affect young people, especially in relation to their self-perceptions and understanding of health and HIV
but also in terms of their difficulties with adherence. This research will also have to take into consideration
potential forthcoming reductions in the recommended dosing of EFV in light of recent discoveries54 and
what the consequences of such changes might be for side effects and for the future of SCT or other
interventions involving treatment breaks.
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Chapter 6 Conclusions
In conclusion, in the BREATHER trial, a global study involving young people from diverse geographical,ethnic and sociocultural backgrounds, the non-inferiority of SCT compared with CT using EFV-based
combination ART was demonstrated.
Overall, 93% of young people remained virally suppressed with a very small difference (1.2%) between
the arms favouring SCT. There was no detectable difference in immunological parameters, the
development of viral resistance or markers of inflammation, nor was there a difference in the number
of AEs between arms; however, a lower number of reported ART-related AEs was observed in the CT arm.
Importantly, contrary to pre-study perceptions of some, there was absolutely no evidence of lower
adherence in the CT arm than in the SCT arm.
Allowing short weekend breaks in daily pill taking was well accepted by participants, who showed a strong
preference for the SCT strategy as it allowed for a more normal weekend lifestyle and had a positive
impact on their social activities.
BREATHER was associated with an important reduction in drug exposure for the SCT arm. Lower drug
exposure reduces the likelihood of longer-term toxicity and could accrue significant cost savings such that,
in resource-limited settings, this could allow more young people to initiate ART (important in view of
recent changes in World Health Organization guidelines recommending treatment for all63).
The BREATHER trial represents an important first step in designing therapeutic strategies for young people
that, without compromise of virological control or immune function or other hazards, permit normalisation
of the adolescent and youth experience. This has relevance to the design of future studies, particularly
those involving drugs with longer half-lives and a higher threshold to resistance, increasing numbers of
which are becoming available.
The results of this study will be applicable in well-suppressed and adherent young people on a regimen
containing a drug with a long half-life, providing that the results of the 2-year long-term follow-up phase
of the BREATHER trial confirm that SCT is an effective and a safe strategy. Further pragmatic studies
including follow-up under routine clinical conditions in settings with less frequent VL monitoring may be
required to confirm the applicability of this strategy in real-life situations. It is also possible that this
approach could be undertaken with other suitable long-acting drugs (e.g. tenofovir alafenamide) and/or
drugs with a higher barrier to resistance (e.g. dolutegravir).
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Appendix 1 The BREATHER trial protocol changes
taken directly from protocol version 1.9
Changes to protocol version 1.7 creating version 1.9 1st April 2014 (the changes 
made from version 1.7 to 1.8 12 March 2014 are as outlined below except that it was 
planned that adherence questionnaires would be done once a year during the long 
term follow up. It was subsequently decided that adherence questionnaires should be 
done every 12-16 weeks and acceptability questionnaires at re-starting continuous 
ART or at the end of the study. It was also decided that a CRF should be completed 
every 12-16 weeks rather than once a year during the long term follow up, and that 
tanner scales and routine FBC and biochemistry results did not need to be collected. 
Flowsheet 1.13, section 8.10 and the new information sheets and consent forms in 
appendices 17-20 were updated to reflect this. Version 1.8 was approved by the Irish 
Medicines Board before this update was made, but not reviewed or approved in the 
other countries) 
 
Major changes: 
General Information, Abbreviations, sections 3.2, 10.4, 15, appendix 16: The MRC 
CTU became part of UCL on 1st August 2013. All MRC CTU employees are now 
employed by UCL and UCL is responsible for providing indemnity for sites in the 
UK. 
General Information, Abbreviations, section 3.2, 10.3, appendix 16: INSERM-SC10 
became INSERM SC10-US019 
Section 1.6, 1.7.2, 7.12, 8.11.1, appendix 12: End of trial definition changed from 
once last participant enrolled has been followed for 48 weeks (now defined as 
completion of main trial) to once all participants have had their final long term follow 
up visits 
Section 1.6, 1.13, 4.1, 8, 8.10, 8.11.1, appendix 15: The TSC recommended that 
participants are followed for 2 years after completion of the main trial (long term 
follow up). A flowsheet has been generated for this long term follow up including 
completion of adherence questionnaires every 12-16 weeks, completion of 
acceptability questionnaires at re-starting continuous ART or at the end of the study, 
and storage of a plasma sample at the final visit for future HIV-related tests 
Section 1.6, 1.13, 7.12, 8.10, appendix 15: Management of HIV-1 RNA viral load 
should continue as specified in appendix 15 if the participant continues follow up in 
the trial after the main trial is completed 
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Section 7.12, appendix 12: The TSC recommended that young people be allowed to 
stay on SCT between the main trial completion and publication of the results provided 
that they are virologically suppressed, the clinician and family agree, and 12-16 
weekly viral load monitoring can be performed  
 
Appendices 17-20: New information sheets added for long term follow up in SCT 
(appendix 17) and CT (appendix 19) arms for parents/carers, young adults, young 
people, children and children taking medicines long term (unaware of diagnosis), and 
new consent forms for parents/carers and young adults and assent forms for young 
people/children for SCT (appendix 18) and CT (appendix 20) arms 
 
Minor changes: 
General Information: Clarification that funding by PENTA from current EU grant is 
available until 2015 
General information, section 3.2: Updates made to participating centres and MRC 
CTU contact details 
Sections 2.6, 8.1, 8.4, 8.11.2, 10.3, appendix 11: minor clarifications to text 
Section 10.1, 10.2: Clarification that pregnancies are notable events and should be 
reported on an SAE form, and that if a participant on the SCT becomes pregnant they 
should return to CT 
Section 8.10, 10.2: Safety reporting to continue as per protocol for entire duration of 
follow up within the trial  
Appendix 11: Proviral DNA will not be quantified in young people in the pilot phase 
of the SCT arm at weeks 1, 2, and 3 as PBMCs are required for this but only plasma 
was collected at these visits. Low level viral loads will be done to <10 c/ml rather 
than <3 c/ml as this is what is currently feasible 
Appendix 12 – qualitative sub study consent forms – clarification that there will be 2-
3 interviews (rather than just two) 
Appendix 16: Other updates to contact details (non-MRC CTU)  
Changes to protocol version 1.6 creating version 1.7 24 April 2013 
 
Major changes: 
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Sections 1.3, 1.8, 4.1, 5.5, 11.3, Appendix 1, Appendix 3: Sample size updated to a 
minimum of 160 participants 
The TSC and IDMC supported a proposal to enrol as many young people as possible 
in the time available, even if this exceeds 160. They agreed that this would enhance 
the power of the study and allow continuing collaboration with new centres. 
Section 1.6, 4.1: Recruitment period updated to 27 months, i.e. up until end of June 
2013 
Section 11.3: Justification for updating sample size to a minimum of 160 and a 
maximum of 220 participants added  
Section 2.6, 8.5, 13.2: Minor re-wording to clarify that not all resistance tests will 
need to be done centrally and may be performed locally where feasible.  
Appendix 11: Clarification that resistance testing will be performed locally and that if 
this is not possible, or the amino acid sequence cannot be provided in a FASTA file 
format, they will be performed centrally. 
The TMG agreed that centralised viral load testing on samples ≥50 c/ml would 
introduce non-random bias and that the variation between assays that exists in reality 
should not systematically bias randomised comparisons. 
Section 11.4: Stopping criteria updated 
Appendix 12: Inclusion of data collection with non-trial participants; focus groups 
with non-trial participants and interviews with carers. These and the associated 
information sheets and consent forms will have ethical approval sought from 
LSHTM) 
 
Minor changes: 
 
Section 1.6: Clarification that the end of trial will be once the last participant 
randomised has completed 48 weeks of follow-up. 
Section 1.7.3: Minor re-wording 
Section 1.8: Clarification that participants that have completed 48 weeks of follow-up 
will be seen every 12 weeks thereafter until the end of the trial. 
Section 4.3: A scan of the original CRF may be sent to the Trials Unit for data entry 
for some centres 
Section 5.5: There will be single centre in the Ukraine, therefore wording updated 
Section 6.1.2: Clarification that RA/RO phenotypes to be collected if available 
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Section 7.5.2: Minor re-wording 
Section 11.1: Update to 24 years for 18-21 year age strata (not updated in protocol 
version 1.6 in error) 
Section 11.4: Updated wording regarding IDMC review of pilot and outcome 
Section 18: Clarification in Changes to protocol version 1.5 creating version 1.6 29 
June 2012 that the Qualitative Substudy information sheets were updated as described 
(and not the main trial information sheets) 
Appendix 12: Clarifications that Dr Sarah Bernays will also be managing the 
qualitative study, trial participants must be aged 10-24 year olds, three interviews will 
be conducted where feasible, exploring participants’ interest in contributing an audio 
diary in the latter half of the trial will not necessarily need to be at around 36 weeks, 
focus groups will be conducted in Uganda (with trial participants), incentives will not 
be provided for focus groups but food and refreshments will be provided and travel 
costs reimbursed 
Appendix 15: Clarifications added to flow chart for managing viral loads regarding 
viral load results reported as <XX c/ml where XX>50 
Appendix 16: Marc Lallemant changed to Tim Cressey in TMG. Anna Turkova added 
to TMG. 
 
Changes to protocol version 1.5 creating version 1.6 29 June 2012 
 
Major changes: 
 
Abbreviations and Glossary, sections 1.3, 2.5, 5.1, 9.2, Appendix 12 Qualitative 
Substudy information sheets for parents/carers, young adults and young people: 
Upper age limit for young person/people eligible for trial entry increased to 24 years 
of age 
 
Sections 1.6 and 4.1: Recruitment period updated to 24 months in total 
 
Appendix 12: Addition of USA to Qualitative Substudy 
 
Minor changes: 
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General Information, sections 3.2, 5.5, Appendix 14 and Appendix 16: Participating 
centres updated 
Sections 4.2 and 11.6: Correction of typing error – young people with a HIV-1 RNA 
≥50 copies/ml at week 8 (pilot phase only) must have a repeat test on a separate 
sample within 1 week 
Appendix 15: Clarification that participants in the CT arm should have a repeat VL on 
a separate sample within 1 week if any VL ≥ 50. Clarification that if a participant 
enrolled to the pilot phase had a confirmed blip at any of weeks 1, 2 or 3 in the pilot 
phase, then they would need to return to CT if they have 2 unconfirmed blips in the 
main phase of the trial. 
 
Changes to protocol version 1.4 creating version 1.5 19th December 2011 
 
Major changes: 
 
Text relating to the pilot phase only now appears in grey; including in the flow charts 
1.09, 1.10 and Appendix 15, and has been removed in the Sample Patient Information 
Sheets (Appendix 1). 
Section 2.6 Risks and benefits: The statement ‘Safety in the pilot study will be 
assured before moving to the main trial’ has been replaced with ‘Data from the pilot 
phase has been reviewed by the IDMC who identified no safety concerns and 
recommended that recruitment continue’. This statement has also been added to the 
Patient Information Sheets in Appendix 1. 
Section 6.1.1 Enrolment and consent: Minor re-wording of text removing reference to 
pilot. 
 
The requirement for local HIV-1 RNA viral load measurement at randomisation 
(week 0) has been removed affecting:  flowsheets in section 1.11 and 1.12, and 
section 6.2. 
 
Screening visit (section 6.1.2): Previously stated screening should take place no more 
than four weeks prior to randomisation (week 0) and ideally two weeks before. This 
has been changed to state that randomisation (week 0) should take place no more than 
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four weeks after screening and ideally as soon as possible after eligibility has been 
confirmed. This change is also reflected in section 7.3. 
 
For young people randomised to SCT, a comment has been added in sections 1.2, 4.1 
and 7.3 to state that if alternative consecutive days to Saturday-Sunday or Friday-
Saturday are taken off ART to better suit a particular young person’s normal routine 
then the days should be decided at enrolment and remain constant throughout the 
study period. This has also been added to the Patient Information Sheets in Appendix 
1 stating that young people/parents/carers should discuss this with their nurse/doctor 
prior to enrolment. 
 
Changes to the inclusion and exclusion criteria (affecting sections 5.1 and 5.2): 
Participants can be on a regimen containing NtRTIs (i.e. 2 NRTIs/NtRTIs and EFV). 
This has been clarified in sections 1.3, 1.8, 5.1, and 7.8. 
Previously, young people who had experienced a single viral load >50 but <400 
copies/ml in the last 12 months could be enrolled. This has been changed to state that 
young people who have experienced a single viral load >50 but <1000 copies/ml in 
the last 12 months can be enrolled (provided at least 3 measurements <50 copies/ml 
are available from the last 12 months, including screening). 
Participants are no longer required to have started HAART naïve. Previous dual 
therapy and/or  substitution of NRTIs is allowed providing any changes were not for 
disease progression, immunological or virological failure. The definition of 
virological failure has been clarified. Previous ART monotherapy (except for the 
prevention of mother-to-child transmission) has specifically been added as an 
exclusion criterion. 
 
Appendix 1 – An information sheet for children unaware of their diagnosis has been 
added  
The role of the Research Ethics committee has been modified in the parents/carers, 
young adult, and young people information sheets to state that their task is to check 
the study and make sure as far as possible; no harm comes to anyone from being part 
of the study. 
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Appendix 2 – Sample Consent Forms: Statement regarding use of anonymised blood 
samples in consent forms for parent/carers and young adults has been amended to 
state that they will only be used for ethically approved studies. Assent form for 
children unaware of diagnosis added 
 
Appendix 5 – Acceptability questionnaire for carers – Weekends off group – 
Restarting continuous ART or at end of study: Question 5 reworded into two parts (a 
and b) to ask about the difference for the child before and after the weekend. Question 
6 reworded into two parts (a and b) to ask about the difference for the carer before and 
after the weekend. 
Acceptability questionnaire for young people – Weekends off group – Restarting 
continuous ART or at the end of study: Additional question introduced at beginning to 
ask who gives the young person their medicines (for consistency with the other 
questionnaires). Question 3 reworded into two parts (a and b) to ask about the 
difference for the young person before and after the weekend. Additional question 
introduced after this (now Q4) to ask about difference before and after the study. 
 
Appendix 12 - Qualitative Substudy – Patient Information Sheets - Wording regarding 
timing of interviews modified; first interview to take place in early stages of the trial 
and second to take place towards the end of the trial. Clarification that a third 
interview may be conducted if feasible and that travel expenses to attend interviews 
will be reimbursed.  
A witness signature section has been added to all the consent forms relating to this 
substudy in the case that the participant/carer is unable to sign and uses a thumbprint. 
 
Minor changes: 
 
Minor re-wording for clarification: general information; 1.6; 1.7.3; 5.1; 6.1.1; 6.2; 
Appendix 11 
Updates to contact details: general information; Appendix 16 
 
Changes to protocol version 1.3 creating version 1.4 21st January 2010  
 
Major changes: 
DOI: 10.3310/hta20490 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 49
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Butler et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
81
Prof. Ian Weller, Chair of BREATHER Steering Committee added to authorisation of 
protocol. 
Compliance and funder details changed 
Section 1.2, 1.5, 1.8, 1.9 -1.12, 4.1, 4.2, 7.1, 7.2, 7.6  PIS:  Addition of viral load 
measurements and blood stores at weeks 1, 2, 3 and 8 for participants randomised to 
continuous ART in the pilot phase 
Section 1.9-1.12, 8.5: Reduction of timepoints for cell storage 
 
Section 4.2, 11.6: clarification of main trial primary outcome measures for 
participants enrolled in the pilot phase 
 
Minor changes and corrections: 
 
General information: Reference to EuroCoord added 
Flowsheet 1.10: Flowsheet for CT Participants in the Pilot phase added 
Appendix 2: Minor re-wording of the consent forms 
Appendix 16: IDMC membership added 
 
Changes to protocol version 1.1 creating version 1.3 8th December 2010. 
 
Note: This protocol is named version 1.3 8th December 2010 to avoid confusion with 
protocol version 1.2 dated 12th August 2010 which was submitted to the Thai 
Research Ethics Committee in error.  
 
Major changes: 
 
General information: committee membership and medical experts moved to Appendix 
16 
Section 1.9, 1.10, 1.11: Tanner stage examination moved from screening to 
randomisation visit. Calcium and phosphate now only at baseline and annually 
thereafter. Biochemistry to be carried out as per local practice. 
Section 3.2, Uganda and Romania added to list of participating countries.  
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Section 5.2 : additions to exclusion criteria: creatinine, AST or ALT of grade 3 or 
above at screening; NVP or boosted PI regimen. 
Section 5.3, specified that siblings can be allocated into the same arm.  
Section 7.3, clarification that participants in pilot can change days off from 
Saturday/Sunday to Friday/Saturday, after the pilot if they wish; removal of 
specification that morning ART must be not be taken. 
Section 8.2, collection of ethnic origin justified and reference [39] added. 
Section 8.7: clarification of use of diary to provide information on adherence. 
Appendix 1: Deletion of reference to text-back; clarification of where information is 
country/substudy specific. 
Appendix 2: Addition of consent to receiving text messages, where possible. 
Appendix 4 and 5. Adherence and Acceptability questionnaires revised. 
Appendix 7. An alternative design for the participant diary added. 
Appendix 9. Toxicity grading tables updated with  August 2009 revision. 
 
Contacts and references updated. 
 
Minor changes made for clarification; Page 1, Sections 1.2, 1.3, 1.5, 1.9, 1.10, 1.11, 
2.2.1, 2.4, 5.1, 5.2, 6.2.1, 7.1, 8, 8.2, 8.4, 8.5, 8.7, 8.8, 8.10.1, 10.4, 11.4, Appendices 
14 and 15. 
 
 
Changes to protocol version 1.0 creating version 1.1 12th April 2010: 
 
Major changes: 
1) Viral load cut off of 10,000 taken out of section 1.8, 7.2 and patient 
information sheets. 
2) For pilot phase, option of fri/sat off ART and the attending phlebotomy visit 
on a Tuesday has been taken out so that the viral load is taken before 
recommencing ART (i.e Sat/sun off ART, viral load taken on Monday before 
ART recommences).  
3) Clarification of how the young people in the pilot phase will be handled in 
terms of the primary outcome.  
4) Week 1 phlebotomy visit in main trial taken out (flowsheet 1.10 amended) 
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5) Centralised viral loads to be measured at end of trial (section 8.5 and appendix 
11). 
6) Change of lipodystrophy assessment from screening visits to week 0 
(flowsheets 1.9-1.11, section 8.2). 
 
Changes to structure and minor changes to text: 
7) Text about pilot phase and main trial specific requirements taken out of 
sections, 1.8, 4.2, 4.3, 6.2.2 and 6.2.3 and added to sections 1.2, 1.4, 1.5, 4.1, 
4.2 and section 7 (7.1-7.5). 
8) Thailand HIV-NAT to take part in adherence MEMS cap sub study (section 
1.7.3). 
9) Changes to wording of inclusion criteria (items 3 and 4).  
10) Procedures for assessing efficacy text moved from section 8.9 to 4.3. 
11) Clarification in text to sections 8.7.and 8.8 to state that both careers and 
participants should complete questionnaires, where applicable. 
12) Clarification that week 8 visit is for the pilot phase SCT arm only, sections 1.5 
and 8.5 have been amended). 
13) Abbreviations and Glossary updated. 
14) Contacts updated. 
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Appendix 2 The BREATHER trial Independent
Data Monitoring Committee and Trial Steering
Committee meeting dates
Independent Data Monitoring Committee
l 28 October 2011.
l 5 September 2012.
l 31 July 2013.
l 7 February 2014.
Trial Steering Committee
l 16 December 2010.
l 16 December 2011.
l 16 December 2012.
l 19 December 2013.
l 18 December 2014.
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Appendix 3 The BREATHER trial patient
results leaflet
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Appendix 4 Presentation of the BREATHER trial
results at the Conference for Retroviruses and
Opportunistic Infections 2015
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Appendix 5 Adherence questionnaire
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